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Abstract
In the 21st century, cancer is becoming the curse of the ageing population
in developed countries. No satisfactory therapies are available for many
tumour types, and application of existing therapies is limited by severe side
effects. Thus, there is a great need of new approaches in cancer treatment.
DAB-Am16 is a dendritic polymer with a globular structure, consisting of
poly(propylene imine) branches that emerge from a diaminobutane core.
Its intrinsic tumoricidal activity in mouse models was published in 2005,
but no information on the mechanism of action was available. This thesis
presents novel findings on the pathways underlying the anti-cancer activity
of this dendrimer in vitro and in vivo.
Extensive chemical characterisation of DAB-Am16 confirmed its stability
and purity. Severe time- and concentration-dependent cytotoxicity was
observed for a panel of human tumour cell lines, while a small population
of persisters was identified. Toxicity was accompanied by a delayed or
abrogated cell cycle. There was an increased number of S phase cells,
while the ability to synthesise DNA or to undergo mitosis was progressively
lost with increasing DAB-Am16 concentration. The following cell death
was found to be apoptotic and was biased in a cell cycle phase dependent
manner. The order of apoptotic events upon DAB-Am16 exposure was
determined.
Finally, an in vivo experiment confirmed that DAB-Am16 has a pro-
nounced effect against human pancreatic cancer xenografts in mice, while
being well tolerated by the animals. Post mortem examination of tumour
tissue revealed cell cycle blockage of tumour cells from DAB-Am16-treated
mice. However, disposition for further proliferation was not diminished,
and no significant difference in tumour vascularisation was observed.
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TIC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Tumour initiating cell
TMRE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Tetramethylrhodamine ethyl ester
TOF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Time of flight
UL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Upper left
UR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Upper right
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1.1 Relevance
Cancer is a collective name for a set of diseases characterised by abnormal
growth of cells that can be derived virtually from any tissue of the body.
This unregulated growth leads to the appearance of malignant tumours,
often capable of spreading into other parts of the body by a process called
metastasis (National Cancer Institute 2012). The incidence of cancer
increases with the age. If untreated, cancer is usually fatal. Currently, the
prognosis differs very much with the cancer type, ranging from more than
90% 5-year survival for testicular cancer to less than 5% for pancreatic
cancer (W. C. Huang 2008; World Health Organization 2011). For the
highly aggressive brain tumour glioblastoma multiforma the median survival
time is approximately 12 months and the survival of more than 36 months
is 3–5% (Barbus et al. 2011; Krex et al. 2007), while cure of glioblastoma
is not possible at all (Stupp et al. 2009). The most successful treatment
of local tumours is surgical removal. However, cancer is often diagnosed
at an advanced stage when it has already spread to remote sites of the
body. In this case, chemotherapy and radiotherapy are used to treat
the disease (Aktories et al. 2005). Besides the limited success of these
treatment modalities, they are usually associated with severe acute as well
as long-term side effects that can themselves lead to death or to secondary
malignancies (Brydøy et al. 2007; Gleeson et al. 2004; Oeffinger et al. 2010;
Travis et al. 2010). Thus, improvement of cancer therapy is a pressing need
in order to improve long-term survival rates and to alleviate side effects.
New approaches to cancer therapy are required to overcome the existing
problems.
Nanomedicine is a new and promising area of medical research. It is
characterised by application of nanotechnology in the medical context.
So far, nanomedical research for cancer applications mostly focused on
drug delivery (e.g. liposomal or nanopolymeric drug carriers) and cancer
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Fig. 1: The dendritic structure. A dendrimer consists of a core molecule
with diverging branches. The branches are built of consecutive monomers.
The outer shell consists of tightly packed functional groups, yielding the
possibility of extensive surface modifications of these multivalent molecules.
The highly symmetric hyperbranching results in a globular molecular shape.
Modified from Shipway (1997).
diagnostics (K. K. Jain 2008; Namiki et al. 2011; Nie et al. 2007; Rawat
et al. 2006; Zhang et al. 2008). The potential of nanoparticles to act as
a new drug class themselves has not been exploited in a broad way. This
thesis focuses on the investigation of the intrinsic anti-cancer effect of the
dendritic nanopolymer DAB-Am16.
1.2 Dendrimers
1.2.1 Features and synthesis
Dendritic nanoparticles have been extensively investigated as drug carriers
for targeted delivery of cancer therapeutics. They are globular synthetic
polymers with a highly defined structure and pronounced monodispersity
which accounts for the specific properties of this polymer class. The
characteristic structural feature of a dendrimer is a core molecule with
monomer units diverging from it. The branching units are arranged layer
by layer in a concentric fashion (Fig. 1).
A dendrimer consists of a core molecule which becomes increasingly
branched during each synthesis step. Fritz Vögtle and coworkers were the
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Fig. 2: Two different approaches to dendrimer synthesis. The divergent
method implies the gradual addition of branches starting from the core mo-
lecule, while the convergent method follows the opposite direction, starting
with peripheral branches and joining them together until they are ready to
be attached to the core. Modified from Shipway (1997).
first to synthesise dendrimers, followed by the synthesis of the first family
of dendrimers by Donald A Tomalia in 1985 (Buhleier et al. 1978; Tomalia
et al. 1985). Tomalia and colleagues used a divergent synthesis approach,
i.e., gradually adding new layers of the repeating unit to the reactive sites
starting from the core molecule. Another synthesis method is the convergent
approach, that has been introduced in 1990 by Jean MJ Fréchet. It starts
with the molecular units that will eventually become the outer shell of
the dendrimer and joins them step by step until attachment to the core
molecule (Hawker et al. 1990). A schematic overview of these two methods
is provided in Fig. 2. Dendrimers can be characterised by the number of
branches added to the core. Generation 1 (G1) dendrimers have one layer
of branches attached to the core moiety, while G2 dendrimers carry two
layers and so on.
One type of dendrimers that has attracted much attention within the
scientific community are the poly(propylene imine) (PPI) dendrimers. Most
often, their core molecule is butanediamine. This core contains 4 sites that
react with polypropylenimine during synthesis. The synthesis process is
illustrated in Fig. 3. With increasing generation number, the density in the
17
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Fig. 3: The divergent synthesis of poly(propylene imine) dendrimers starts
with a Michael addition between acrylonitrile and the diamine core molecule.
This is followed by Raney nickel catalyzed hydrogenation under pressure to
obtain the amino-terminated G1 PPI dendrimer. These steps are repeated
until the desired generation number is obtained. Modified from Bhadra
et al. (2005).
outer layer of the particle also increases up to the point when no further
addition of functional groups to the outer shell is possible due to sterical
limitations: a phenomenon that is referred to as “starburst”.
Another important group of dendrimers are poly(amidoamine) (PAMAM)
dendrimers. Their synthesis also starts with Michael addition between a
core diamine and methylacrylate. This is followed by a reaction with
ethylenediamine. Subsequently, the two reactions are repeated for a defined
number of times, thus creating different generations of dendrimers with
an increasing positive charge density in the outer shell of the particle.
According to the number of completed reaction cycles, these dendrimers are
18
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referred to as G1 (generation 1), G2, G3 and so on. However, if one of the
reaction cycles is halted after the addition of methylacrylate, the outer shell
consists of carboxylate groups and is therefore negatively charged. These
dendrimers are called G2.5, G3.5 etc.
An interesting application of dendrimers in nanomedicine is cancer treat-
ment. Gene therapy targeting the abnormal gene expression observed in
tumour cells is a novel approach. Gene delivery for gene therapy requires
the usage of potent delivery agents. Viral vectors have been used with
great success, especially due to their high transfection efficiency. However,
immunogenicity is a major obstacle to the usage of viral vectors in human
patients. Synthetic nanovectors have a number of features that make them
superior to viral vectors. The major advantage is that nanoparticles can be
designed to exert defined functions while avoiding risks associated with the
use of viruses. For example, it is possible to create nanovectors for drugs
that target specific cells and are not immunogenic. Apart from delivering
genes, nanoparticles can also deliver drugs to tumour cells. Nanoparticles
can be created to have a vast payload of drugs and to be able to release
the drug in a controlled manner. Furthermore, there is evidence for a
successful circumvention of P-glycoprotein induced multidrug resistance
by using nanoparticles as vehicles for conventional drugs (for a review see
Davis et al. 2008). Polycationic dendrimers can build complexes with DNA
(so called dendriplexes) and transfect cells in vitro and in vivo (Merdan
et al. 2002; Navarro et al. 2009). However, their transfection efficiency is
lower than that of viral vectors, and cytotoxicity that could potentially
damage healthy cells remains a problem (Mukherjee and Byrne 2012).
Dendrimers possess a number of interesting chemical and physical proper-
ties. Although drawings of the dendritic structure, e.g. in Fig. 1, generally
imply perfect symmetry with all end groups pointing outward, this isn’t
necessarily the case in real life. A number of simulations as well as exper-
imental studies have been performed to reveal the physical properties of
dendrimers. Lescanec et al. (1990) developed a kinetic growth model to
predict folding of dendritic branches and the distribution of end groups
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throughout the entire dendrimer volume. Similar results were obtained by
other research group using Monte Carlo simulations and a self-consistent
mean field model (Boris et al. 1996; Mansfield et al. 1993). This model was
empirically confirmed by the study of Mourey et al. (1992) who found a
nearly linear increase of the intrinsic viscosity with the dedrimer generation,
and a maximum in the intrinsic viscosity as a function of molecular weight.
Importantly, a molecular dynamic study of Murat et al. (1996) points out
that radius of gyration very much depends on the solvent quality and that
the backfolding of dendritic end groups increases with generation number.
These rather generic simulations on starburst molecules are complemented
by specific simulations on the physical properties of PAMAM and PPI
dendrimers (Cavallo et al. 1998; Naylor et al. 1989). Again, backfolding
of end groups is predicted by several different computational approaches.
Scherrenberg et al. (1998) performed experimental studies as well as mo-
lecular dynamics simulations on PPI dendrimers, showing that dendrimer
dimension increases linearly with the generation number and that PPI
dendrimers possess a fairly flexible overall structure with substantial back-
folding in poor solvents which is in accordance with the more general
predictions of Murat et al. (1996). Additionally, the computations of Welch
et al. (1998) imply that backfolding would increase with increasing ionic
strength of the solvent.
An important property of dendrimers is their low polydispersity. Hum-
melen et al. (1997) report the polydispersity of G5 PPI dendrimers to be
1.002, while Kallos et al. (1991) report a polydispersity of 1.0007 for G4
PAMAM. This is a considerable advantage compared to linear polymers
that often possess a high polydispersity, making it difficult to use these
structurally inhomogeneous polymer solutions in medical context. The high
number of charged outer groups and thus the high surface charge accounts
for the high solubility, miscibility and reactivity of dendrimers (Fréchet
1994). Furthermore, due to their globular structure dendrimers possess a
high surface area compared to their volume allowing tight interactions with
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other molecules or with biological structures, e.g. charged surfaces like cell
membranes.
1.2.2 Medical applications
The first medical application of cationic dendrimers in general, and PAMAM
and PPI dendrimers in particular, was their usage as gene transfection
agents (Hollins et al. 2004; Navarro et al. 2009; Zinselmeyer et al. 2002)
and drug delivery carriers (Esfand et al. 2001; Gillies et al. 2005). This is
due to their high water solubility, high number of outer groups that can
be modified for drug attachment, the internal cavities that can incorporate
drug molecules, and their capability to bind nucleic acids and transfect
cells. Dufes et al. (2005) showed that in vivo administration of complexes
between the dendrimer and the mTNFα expression plasmid DNA to tumour-
bearing mice lead to TNFα gene expression by tumour cells accompanied
by tumour growth delay or regression. However, the authors also found that
PPI dendrimers on their own have an intrinsic effect against cancer cells
in vivo and are well tolerated by the mice. The first report about the anti-
cancer effect of polycations reach as far as into early 1970s (Moroson 1971).
Yet the mechanism that leads to tumour regression under dendrimer therapy
remains unclear and it is important to focus further on the antitumour
effect of dendrimers in order to be able to proceed to clinics one day.
One concern about the use of dendrimers as therapeutic compounds is
that toxicity of positively charged dendrimers is a well-known problem
(Malik et al. 2000). For example, high concentrated anionic nanoparticles
as well as even low concentrated positively charged nanoparticles influence
the integrity of the blood-brain barrier. Lockman et al. (2004) observed an
increased accumulation of labelled sucrose in all brain compartments after
treatment of in situ rat brains with cationic emulsifying wax nanoparticles
at 10 and 20µgml−1 (size: 97.2 ± 68.9nm). This raises concern about
possible leakage of the content of luminal plasma into the endothelial tight
junctions of the blood-brain barrier, subsequent swelling and eventually
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endothelial cell death. On the other hand, it is important to notice that low
concentrated anionic nanoparticles seem to be able to cross the blood-brain
barrier without causing its damage (Lockman et al. 2004) which could have
consequences for the development of new therapeutic applications for the
treatment of brain diseases, e.g. brain tumours.
PAMAM dendrimers up to generation G5 do not seem to have noteworthy
adverse effects when applied in vivo in Swiss-Webster mice at concentra-
tions 5× 10−6, 5× 10−5 and 5× 10−4 mmol/kg even after 6 months lasting
weekly injection as indicated by lack of significant weight difference and
behavioural abnormalities compared to control mice and lack of microscopic
or macroscopic tissue abnormalities. However, in vitro studies with V79
cells (Chinese hamster fibroblast cell line) suggest considerable biotoxicity
(Roberts et al. 1996). The in vitro toxicity is very much generation de-
pendent, resulting in cell death at 1mM for G3, 10µm for G5 and less
than 100 nM for G7, without significant differences between 4 and 24 h
exposure. Notably, the toxicity measurement in vitro occurred not until 6
or 7 days after dendrimer withdrawal and thus reflects not only immediate
cell death, but also impaired long-term proliferation ability. This might
explain the lack of significant differences between the two timepoints. Fur-
thermore, PAMAM dendrimers have been reported to be non-immunogenic
in mice. The biodistribution of these radioactively labelled dendrimers
is generation-dependent. While G3 PAMAM dendrimers preferentially
accumulate in liver, kidney and spleen (up to 15 ID/g(percent injected dose
per gram)), G5 and G7 dendrimers are mostly found in pancreatic tissue
(peak at 32 ID/g at 24 h for G5 and 20 ID/g at 2 h for G7). Additionally,
according to radioactive labelling experiments, G7 is excreted urinary in a
large amount (peak at 74 ID/g after 4 h). However, the authors argue that
the high radioactivity in the urine might be due to metabolic demethylation
rather than glomerular filtration.
To test if surface modifications of dendrimers with free amino groups
would alleviate dendrimer toxicity in vivo, Dutta et al. (2008) examined
haematological, histopathological and biochemical parameters in Wistar
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rats that were treated with functionalised G5 PPI dendrimers. Surprisingly,
although coupling of the tetrapeptide tuftsin (Thr-Lys-Pro-Arg) to the
dendrimer amino groups increased the number of free amino groups on
the surface of the particle, the toxicity of this construct was significantly
lower than that of parental PPI dendrimers. This is thought to be due to
masking of the amino groups by the bulky oligopeptide. Conjugation of
t-BOC and mannose also dramatically decreased toxicity of the particles,
probably by disguising the positively charged functional groups.
As for DAB-Am16, Dufes et al. (2005) could not observe considerable
side effects upon its administration into mice. Results of cytotoxicity
investigations in vitro are presented in the following section.
1.2.3 Cytotoxicity
A range of in vitro cytotoxicity testing methods based on different surrogate
markers for viability or death is available. A comparably high throughput
can be achieved with the MTT, Neutral Red (NR) and Alamar Blue (AB)
assays. The MTT assay is based on the conversion of a yellow tetrazolium
salt to purple, water-insoluble formazan by the mitochondrial succinic
dehydrogenase in metabolically active cells (Berridge, Herst et al. 2005;
Berridge and A. S. Tan 1993; Berridge, A. S. Tan et al. 1996; Mosmann 1983).
AB is a oxidation-reduction indicator that changes its colour upon reduction
by mitochondrial enzymes (Anoopkumar-Dukie et al. 2005; Uzunoglu et al.
2010). However, it has been reported that MTT and AB reduction could be
partly carried out by cytoplasmic or microsomal enzymes. NR is a supravital
dye that accumulates in the lysosomes of living cells (Borenfreund et al.
1985; Hamid et al. 2004; Weyermann et al. 2005). A more detailed insight
into the mechanism of cell death can be achieved by the application of
various probes for flow cytometric analysis.
Mukherjee, Davoren et al. (2010); Mukherjee, Lyng et al. (2010) applied
the MTT, NR and AB assays on HaCaT and SW480 cells after treatment of
the cells with PAMAM G4, G5 and G6. The overall tendency of the three
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assays was in agreement with each other: the EC50 (Effective Concentration
with a 50% toxicity effect) decreased with increasing PAMAM generation
number. However, the EC50 values varied considerably, and the same is
true for the curve progression when the cytotoxicity was plotted against
dendrimer concentration. Treatment time was another factor that led to a
variation in the results of the three assays. In general, the MTT assay was
found to be the most sensitive of the three assays. The NR assay exhibited
a stimulatory effect of the dendrimer on the cells upon exposure to low
dendrimer concentrations. The peak of the stimulatory effect corresponded
to the EC50 of the MTT assay. The transition from non-toxic to toxic effect
in the NR assay curve occurred at the EC50 of the AB assay. Measurements
with Lysosensor confirmed an increased lysosomal activity below and up
to EC50 from MTT assay. This increase in the lysosomal activity was not
visible for up to the first 6 h after dendrimer addition (in fact there was a
decrease of the lysosomal activity below the control during the first 6 h), but
was clearly measurable after 24 h. Mitotracker staining intensity and thus
mitochondrial activity decreased with increasing PAMAM concentration,
thus following the results of the MTT assay. There was no clear, consistent
trend in production of reactive oxygen species (ROS). In HaCaT cells, ROS
production increased up to 1–3 h (dependent on the PAMAM generation)
and decreased afterwards, until it fell below the control level after 4 h, but
it rose again after 24 h. For SW480, ROS production rose during the first
6 h, but fell below the control level after 24 h. The authors explain the
difference in ROS production between the cell lines in the different natural
antioxidant levels. Most ROS production occurs at EC50 of the MTT
assay or below. Apoptotic cell death was confirmed by flow cytometry
(Yo-Pro/PI staining) and with the TUNEL assay. Based on these results,
Mukherjee, Lyng et al. (2010) suggest a mechanism of action that includes
cell entrance either via endocytosis (for high dendrimer concentrations)
or hole formation (for low dendrimer concentrations). The absence of
lysosomal activation during the first 6 h is explained by a lack of lysosomal
involvement in early PAMAM effects as dendrimers taken up by endocytosis
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could escape the endosomes due to the low pK of the amines (3.9 and 6.9)
that can buffer the endosomal pH (proton-sponge hypothesis) (Haensler et al.
1993). Mitochondrial damage by the dendrimer is suggested to induce ROS
production and to disrupt the mitochondrial activity, eventually leading
to apoptosis. This would explain the fact that the MTT assay is the most
sensitive cytotoxicity assay for PAMAM-treated cells. As HaCaT cells
contain significantly more antioxidants than SW480 cells, they can more
efficiently counteract the ROS increase that follows mitochondrial damage at
the first time and at low PAMAM concentrations. At longer exposure times,
the ROS defence mechanism collapses and lysosomal activity increases
as a mechanism to neutralize the dendrimers and to remove damaged
mitochondria (mitophagy).
Due to the high positive charge of cationic dendrimers, interaction with
(negatively charged) cell membranes can potentially lead to cell membrane
damage and cellular toxicity. The following section provides an overview
on how dendrimers are known to interact with synthetic and cellular mem-
branes.
1.2.4 Interactions with lipid membranes
Hong, Leroueil et al. (2006) compared the effect of different polymers on
lipid bilayer and cellular membrane. For this purpose, poly-L-lysine (PLL),
branched polyethylenimine (PEI), diethylaminoethyl-dextran (DEAE-DEX)
as well as G5 PAMAM dendrimers were used. They also tested PEG
and PVA, two neutral polymers. Hong, Leroueil et al. found that while
polycationic polymers are all able to disrupt supported dimyristoylphos-
phatidylcholine (DMPC) lipid bilayers, neutral polymers are not. However,
there are differences in the effects of exposure of the bilayer to different
polymers. According to Hong, Leroueil et al., PLL induces the formation of
new 4.0–4.8 nm deep defects, while PEI only extends naturally pre-existing
depressions with a depth that corresponds to the removal of a full bilayer
(4–5 nm). In contrast, DEAE-DEX causes membrane thinning (2–3 nm),
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probably either by changing the orientation of lipids or by their removal.
All three cationic polymers also cause enzyme leakage (LDH 140 kDa and
LUC 61 kDa) from the cytoplasm when intact cells are exposed to nontoxic
polymer concentrations (6 and 12µgml−1 resulting in >80% cell viability)
for 1 h. Three different experiments show that PEI induces most enzyme
leakage and most small molecule diffusion across the cell membrane. This
might be due to the fact that PEI possesses the greatest charge density of
all tested polymers. The authors also suggest from their data that linear
polymers might be less capable of inducing membrane permeability than
sphere-like (PAMAM), branched (PEI) or ring-containing (DEAE-DEX)
particles.
Mecke, Uppuluri et al. (2004) examined the difference of the influence
of positively and negatively charged G7 PAMAM dendrimers and G7-G5
core-shell tectodendrimers (i.e., higher molecular structures consisting of G5
dendrimers covalently attached to the outer shell of a G7 core dendrimer)
on DMPC lipid bilayer on mica. As phospholipids are an integral part of
cell membranes, this bilayer composition is a good choice to investigate
dendrimer effect on biological membranes. The authors observed that G7
PAMAM dendrimers are capable of creating new holes in the bilayer as well
as expanding pre-existing defects regardless of being positively or negatively
charged, or even destruct the bilayer when applied at a high concentration.
In contrast, tectodendrimers did not induce the formation of new holes,
but attached to the edges of existing defects, moved into the holes and
adsorbed to the mica filling out the entire hole. As a mechanism of hole
formation induced by the dendrimers the authors suggest that due to strong
interaction between the lipids and the dendrimers lipids detach from the
mica and enclose the dendrimers to form dendrimer-filled vesicles.
Studies with Atomic Force Microscopy (AFM) and Optical Waveguide
Lightmode Spectroscopy (OWLS) reveal details about the process of dendri-
mer absorption to the lipid surface and hole creation and extension. Parimi
et al. (2008) scrutinised the interaction of PAMAM dendrimers of different
generations (G2, G4 and G6) with supported DMPC lipid bilayers. They
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found that the dendrimer concentration affects hole formation as well as the
general mode of dendrimer-bilayer interaction. Exposure to 1 and 100 nM
dendrimers leads to a mass loss of the bilayer, which indicates lipid bilayer
destruction at these concentrations. At higher concentration and with
increasing dendrimer generation the bilayer removal effect becomes more
pronounced. However, at 10 nM, OWLS shows an increase of the net mass.
This was true for all tested dendrimer generations. Parimi et al. conclude
that dendrimer absorption outweighs hole formation at this concentration.
AFM experiments visualise the dendrimer-bilayer interactions and due to
specific software also allows quantification of hole formation. At 1 and
100 nM hole formation and lipid bilayer defects extension are observed. The
authors surmise that the formation of lipid-dendrimer aggregates (similar
to dendrisomes) and their removal from the bilayer are responsible for this
effect. While G6 PAMAM dendrimers cause the formation of a bigger
amount of holes, G4 dendrimers form less holes of a bigger size, probably
carrying out more defect extension than de novo hole formation. In general,
G2 dendrimers have a significantly lesser effect on lipid bilayer removal. At
a 10 nM concentration, hole formation as well as dendrimer absorption to
the lipid bilayer are detected. However, the hole formation is decreased
compared to 1 and 100 nM dendrimer concentrations. Again, G2 PAMAM
was less efficient in hole formation than the higher generation dendrimers.
Altogether, the authors deduce from the results that at a concentration of
1 and 100 nM, hole formation is the prevalent way of action of the dendri-
mers on the bilayer, while at 10 nM predominantly an adsorption of the
dendrimers takes place.
A number of studies have been conducted in order to investigate the
efficacy and safety of the use of dendrimers as drug and DNA delivery
vehicles. Toxicity studies revealed that cells remain viable after an exposure
to dendrimers up to a concentration of 500 nM for up to 3 h (Hong, Bielinska
et al. 2004). However, an interaction of positively charged late generation
(e.g. G7) dendrimers with the cell membrane has been observed, eventually
leading to the formation of 15–40 nm holes and leakage of cytosolic enzymes.
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The net negative charge of cell membranes might facilitate the dendrimer-
membrane contact. According to Hong, Bielinska et al., this hole formation
is reversible as cells recover after withdrawal of dendrimers from the growth
medium.
In contrast, uncharged dendrimers do not show interaction with the
cell membrane. This and the fact that higher generations of cationic
dendrimers are more effective than lower generations suggests that a high
cationic charge density (charge/monomer ratio) favours polymer interaction
with cell membrane phospholipids. Nonetheless, an uptake not only of
cationic, but also of uncharged and anionic dendrimers via endocytosis can
be observed. It has been shown that inhibition of different endocytotic
processes with different inhibitors (Brefeldin A, colchicine, filipin, sucrose)
in each case leads to a significantly reduced uptake of positively charged
G4 PAMAM dendrimers (Kitchens, Kolhatkar et al. 2008). The following
section presents an overview of experimental results pointing to endocytotic
uptake of dendrimers.
1.2.5 Evidence for endocytotic mechanism of cell entry
PAMAM G4 dendrimers conjugated with the fluorophore Alexa647 associate
with the cell membrane of HeLa cells within 1 h. However, internalization
partly occurs only after 2 h. After 4 h, no membrane fluorescence is detect-
able any more and the dendrimer accumulates in the perinuclear area. This
process is completed after 12 h, and there is no change in PAMAM dendri-
mer localisation within 48 h (Albertazzi et al. 2010). PAMAM G4-Alexa488
conjugate colocalises with control molecules for clathrin-dependent endo-
cytosis (transferrin) and macropinocytosis (FITC-dextran), but does not
colocalise with EGFP-marked caveolin. After cell entry, it accumulates in
the perinuclear region, colocalising with lysosomal markers (lysosensor),
but not with Golgi apparatus marker (Giantin)(Albertazzi et al. 2010).
Furthermore, colocalisation with TAT (a peptide taken up rapidly by mac-
ropinocytosis and clathrin-dependent endocytosis) also can be observed,
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although TAT enters the cell much quicker than PAMAM G4: already
within 1 h. The speed of PAMAM G4 internalisation was found to be
dependent on the cell line.
Seib et al. (2007) studied the internalisation of linear and branched
PEIs as well as of cationic PAMAM dendrimers (G2–4) in B16f10 mouse
melanoma cells. All polymers were used at 140 nM, and measurement
was performed for 2 h. The above mentioned polymers were conjugated
with Oregon Green (OG). The authors propose a cholesterol-dependent
internalisation of PAMAM G4 as they observed 44% reduction in PAMAM
internalisation when cells were treated with MβCD, a putative inhibitor of
pinocytosis. The same was true for branched PEI. However, a markedly
increased uptake of linear PEI was detected under the same conditions,
which the authors explain by a putative existence of different binding sites
for branched and linear PEI on the cell membrane. These experiments
were performed at significantly lower concentrations than those reported
to induce enzyme leakage from cells by Hong, Bielinska et al. (2004) (200
and 400 nM for KBpLuc and Rat2pLuc cells, respectively) or membrane
damage by Hong, Leroueil et al. (2006) who used PAMAM G5 at 6 and
12 µgml−1 which corresponds to a concentration of ∼ 200 and 400 nM, re-
spectively. In contrast, Parimi et al. (2008) observed membrane damage
at as low concentrations as 1 and 100 nM. However, supported DMPC
membranes are models that reflect some, but not all properties of plasma
membrane, so comparison between the above-mentioned cellular experi-
ments can be carefully interpreted as a hint that endocytosis might occur
at lower concentrations than membrane damage. Precise comparison of
minimal concentrations at which endocytosis and hole formation occur at
the same treatment conditions of the same cell lines are necessary to test
this supposition. It is also important to keep in mind that the dendrimers
used in studies of Albertazzi et al. and Seib et al. are conjugated with
fluorescent probes that might themselves enhance endocytosis to a large
extent. For instance, OG is known to enhance transfection activity of
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PAMAM dendrimers, presumably through hydrophobic interactions leading
to disruption of endosomal membrane (Yoo et al. 2000).
Perumal et al. (2008) found that PAMAM dendrimer uptake (∼ 690 nM,
1 h) into A549 lung epithelial cells was significantly reduced upon reduction
of the incubation temperature from 37 °C to 10 °C by 80–90% for positively
and negatively charged as well as neutral G4 dendrimers. Inhibition of cellu-
lar metabolism by treatment with deoxyglucose and sodium azide decreased
the cellular uptake of the dendrimers by 40–50% for charged and by 70%
for neutral dendrimers. Thus, the uptake of PAMAM dendrimers seems to
include an energy-dependent as well as an energy-independent mechanism.
These authors also found that upon inhibition of fluid-phase endocytosis
by sucrose, dendrimer internalisation was also markedly decreased, most
prominantly for G4-NH2 dendrimer (80%). In contrast to the findings of
Albertazzi et al., Perumal et al. (2008) propose a non-clathrin-mediated
endocytosis pathway for PAMAM uptake, as chlorpromazine (a specific
inhibitor of clathrin-mediated endocytosis) was able to reduce the intern-
alisation of transferrin but not of PAMAM G4. Interestingly, filipin (an
inhibitor of caveolae/cholesterol dependent endocytosis) had different effects
on the three dendrimers used in this study: while G4-COOH uptake was
decreased to the same extent as the uptake of lactosylceramide (marker
for caveolae-dependent endocytosis), no effect on the neutral dendrimer
and a significant increase of G4-NH2 uptake were observed. These results
contradict the observations of Kitchens, Kolhatkar et al. (2008) who ob-
served a significant inhibition of G4-NH2 uptake by Caco-2 cells in the
presence of filipin. This might be due to the difference in cell features, as
Perumal et al. used A549 lung epithelial cells. Inhibition of macropinocyt-
osis and phagocytosis by cytochalasin did not have any effect on the uptake
of all three dendrimers (positive control: FITC-dextran) by A549 cells.
Nocodazole (an inhibitor of microtubules and thus of vesicular movement)
only reduced the uptake of the anionic dendrimer (by 50%), but not of
the cationic and the neutral ones. An increase of the pH of intracellular
organelles by ammonium chloride treatment decreased the uptake of the
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anionic dendrimer, and slightly increased the uptake of G4-NH2. Uptake
of the neutral dendrimer was not altered. Intracellularly, the cationic
dendrimer was found not to colocalise with lysotracker, while the other
two dendrimers did. G4-NH2 accumulated in the cell periphery. Perumal
et al. suggest a caveolae-mediated uptake of anionic dendrimers, and a
non-clathrin and non-caveolae dependent uptake mechanism for cationic
and neutral dendrimers. However, all three dendrimer types seem to be
taken up by endocytosis according to their results.
Kitchens, Foraker et al. (2007) investigated the mechanism of entrance
of differently charged PAMAM dendrimers into Caco-2 intestinal epithelial
cells. They found that at 100 nM, low (G2) as well as higher generation
dendrimers (G4) colocalise with clathrin, with the lysosome-associated
protein 1 (LAMP-1) and the early endosomal antigen 1 (EEA-1). Notably,
when comparing the results of colocalisation experiments after 20min
and after 60min, they observed an increased colocalisation of G2-NH2
dendrimers with LAMP-1. When Kitchens, Foraker et al. investigated the
appearance of microvilli layer of the cells with TEM after 2 h treatment
with dendrimers, they noticed that G2-NH2 dendrimers did not damage
the microvilli, while G4-NH2 had a destructive effect on them. This effect
increased with the concentration. These findings of Kitchens, Foraker
et al. correspond with reports on hole formation in cell membrane by
positively charged dendrimers (Hong, Bielinska et al. 2004; Hong, Leroueil
et al. 2006; Mecke, Majoros et al. 2005; Mecke, Uppuluri et al. 2004;
Parimi et al. 2008). On the other hand, Akesson et al. (2010) investigated
the effect of PAMAM G6 on lipid vesicles and their results suggest that
PAMAM G6 binds to the lipid membrane and at higher concentrations
leads to aggregation of larger vesicles by electrostatically bridging the
lipids, thereby deforming but not damaging the vesicles. The authors
conclude that at physiological concentrations, PAMAM G6 would not
permeate phosphatidylcholine/phosphoglycerol membranes, however they
do not exclude the possibility of another nature of interaction between
PAMAM G6 and negatively charged phosphatidylcholine in cell membranes,
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as well as defect propagation in imperfect membranes. Evidence for an
endocytotic uptake mechanism of PAMAM dendrimers as well as lysosomal
colocalisation was also found by Saovapakhiran et al. (2009).
The cell entrance mechanism of SuperFect, a commercially available
fractured G4 PAMAM dendrimer often used as transfection agent (Merkel
2009), was investigated by Manunta, P. H. Tan et al. (2004). By deple-
tion of cellular cholesterol with MβCD, filipin III and nystatin as well
as reconstitution of cholesterol content while or after this treatment in
EA.hy 926 (human endothelial hybridoma), HEK293 (human embryonic
kidney) and CHO (Chinese hamster ovary) cells, they found dendrimer
binding to the cell membrane and entrance into the cell being cholesterol de-
pendent. Because of colocalisation of dendriplexes (complexes of dendrimer
with nucleic acid) with glycosphingolipid GM1 the authors conclude that
lipid rafts are involved in the endocytotic uptake of dendriplexes by cells. In
contrast, depletion of plasma membrane cholesterol by filipin III in HepG2
and HeLa cells that usually contain only little cholesterol, even increased
the transfection efficiency with lipofectamine (significantly only in HepG2)
(Manunta, Nichols et al. 2006). Inhibitors of clathrin-dependent endocyt-
osis (chlorpromazine), phagocytosis and macropinocytosis (cytochalasin D),
and macropinocytosis (wortmannin and LY294002) also did not decrease
transfection efficiency, while a significant increase in transfection efficiency
was observed in EA.hy 926 and HepG2 cells. Overexpression of AP180
(a dominant negative mutant of the clathrin accessory protein) and cave-
olin 1 led to increased uptake and transfection efficiency. Colocalisation of
dendriplexes with caveolin 1 as observed with confocal microscopy further
confirms the involvement of the caveolae-dependent endocytosis pathway
in dendriplex uptake (Manunta, Nichols et al. 2006).
In summary, all of these studies confirm the uptake of PAMAM dendri-
mers via endocytosis. However, more detailed studies of the type of endo-
cytosis yield contradictory results. Focusing specifially on cationic PAMAM
dendrimers, involvement of clathrin-mediated endocytosis was suggested
by Albertazzi et al. (2010); Kitchens, Foraker et al. (2007), involvement
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of caveolae-dependent endocytosis was observed in studies of Kitchens,
Kolhatkar et al. (2008); Manunta, Nichols et al. (2006); Seib et al. (2007),
and macropinocytosis was suggested by Albertazzi et al. (2010). On the
other hand, no involvement of neither clathrin- nor caveolae-mediated en-
docytosis nor macropinocytosis was found by Perumal et al. (2008), and no
involvement of caveolae-dependent endocytosis was observed by Albertazzi
et al. (2010). However, all of these studies used different generations of
PAMAM dendrimers as well as different cell lines. Cell lines differ with
respect to their plasma membrane lipid composition which might highly
influence the endocytotic mechanisms used by the cells. Furthermore, given
the observations that the capability to insert holes into artificial and biolo-
gical cell membranes changes with the generation number, the endocytotic
mechanism might be altered as well. For instance, it is conceivable that
higher generation dendrimers exert a tighter interaction with negatively
charged phospholipids within plasma membrane rafts, while being less prone
to cholesterol-dependent internalization due to their bulkier size.
Although the studies listed above refer to PAMAM dendrimers, it can
be assumed that their implications are also important for PPI dendrimers
due to the very similar structure and physico-chemical properties.
1.2.6 Chemical characterisation
Safe application of dendrimers as human therapeutics requires a precise
structural characterisation including quantification of possible impurities
(e.g. dendrimers with structural defects or presence of other compounds in
the sample). Analysis of structure-activity-relationships and thus future
modification of the chemical structure in order to improve activity and safety
require the knowledge of the precise chemical structure of the administered
agent. Furthermore, stability of the pharmaceutical compound over time can
only be monitored if methods for structural characterisation are available.
The structure and purity of PPI dendrimers have been characterised by
mass spectrometry (MS) and nuclear magnetic resonance (NMR) (Chai
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Fig. 4: Scheme of possible decomposition reactions of DAB-Am16 during
MS/MS according to McLuckey et al. (2000).
et al. 2001). These techniques allow to reveal the molecular composition a
sample in a quantiative way.
A generalised scheme for the various possible reactions that PPI dendri-
mers might undergo during the MS/MS measurements has been proposed
by McLuckey et al. (2000). According to this scheme, a nucleophilic sub-
stitution occurs whereby a tertiary nitrogen situated in one of the inner
shells serves as a nucleophile. This nitrogen atom attacks an α-carbon
atom adjacent to the next nitrogen. If this carbon atom is further in the
interior of the dendrimer (i.e., closer to the core than the nucleophile),
the reaction is called “process A”. If the attack occurs into the opposite
direction, the reaction is designated “process B”. The layer in which the
protonated nitrogen atom is situated, is termed Gn, whereby n refers to
the generation number. Herein, n = 0 represents an attack onto one of the
core /alpha-carbon atoms (Fig. 4).
Based on this scheme, various charged fragments can be predicted to
be seen in the spectrum. After fragmentation of the molecular ion (M +
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H)+ of the DAB-Am16 dendrimer 6 charged fragments should be observed
(Fig. 5).
The experimental results support the theoretical predictions. McLuckey
et al. applied electrospray ionisation (ESI) onto DAB-Am16 molecules and
subsequently recorded the spectrum of the molecular ion in ion trap tandem
mass spectrometry. All of the predicted peaks were observed in the mass
spectrum except of G2(B) that fell below the cutoff m/z value. Additionally,
a peak at m/z 269 appeared that can be explained by dissociation of a
fragment structurally correspondng to G2(A) product from G0(B)q. The
authors argue that similar dissociation reactions might have contributed to
the peaks assigned to products of fragmentation reactions in Fig. 5.
To investigate the influence of different solvents on PPI G3 dendrimer
conformation, Adhiya et al. (2002) applied matrix-assisted laser desorption
ionisation (MALDI) or electrospray ionisation (ESI) to the dendrimer using
solvents with different properties for sample preparation or spraying process.
The molecular ion was subsequently subjected to post-source decay (PSD)
and collisionally activated dissociation (CAD) measurements. The authors
found a clear dependence of MS/MS spectra from the solvent used during
ionisation. G1(A) and G2(A) fragmentations do not seem to occur when
DAB-Am16 was dissolved in a non-polar, poor solvent (benzene). This is
explained by backfolding of outer dendrimer branches and formation of
hydrogen bonds between outer and inner amines.
NMR studies by Chai et al. (2001) confirmed that PPI dendrimers mostly
adopt an extended conformation in polar solvents and a folded conformation
in non-polar solvents. Interestingly, while structural defects were found in
G4 PPI dendrimers (DAB-Am32), no such defect were seen in DAB-Am16.
1.2.7 DAB-Am16 dendrimer
The present study focuses on generation 3 polypropylenimine (PPI) dendri-
mers with a diaminobutane (DAB) core and 16 amino groups in the outer
shell. G3 PPI dendrimers are well tolerated in vivo while having a profound
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Fig. 5: Predicted fragments of DAB-Am16 due to mass spectrometric
ionisation of the molecular ion (McLuckey et al. 2000).
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anti-tumour effect (Dufes et al. 2005). Thus, this section gives an in depth
introduction of this particular dendrimer.
DAB-Am16 has a molecular weight of 1.687 kDa and a hydrodynamic
diameter of 1.9 nm (Voegtle 2000). Fig. 6 shows the chemical structure of
DAB-Am16. The unique synthesis pathway leads to a polydispersity index
of approximately 1 and a low number of defects compared to stochastically
formed polymers (Hummelen et al. 1997). This implies that DAB-Am16
has a similarly well-defined chemical structure as conventional drugs. The
molecular weight is also similar to conventional drugs (e.g. cyclosporine
1.2 kDa), but higher than that of standard anti-cancer agents (e.g. cisplatine
0.3 kDa, doxorubicin 0.5 kDa, etoposide 0.6 kDa).
Fig. 6: The chemical structure of DAB-
Am16.
It has previously been shown
that upon exposure of cells to
DAB-Am16, this dendrimer enters
the cell nucleus within 30min and
binds to the DNA in a manner sim-
ilar to doxorubicin. In vivo exper-
iments on mice with tumour xeno-
grafts revealed that DAB-Am16
dendrimers as well as fractured
G4 PAMAM and linear PEI have
an intrinsic anticancer activity
against colorectal, cervix and epidermoid carcinoma and leukemia (Dufes
et al. 2005). The anti-cancer activity of DAB-Am16 in mice exceeds that
of conventional antineoplastic drugs without having severe side effects.
However, the mechanism of action of DAB-Am16 remains to be elucidated.
Omidi et al. (2005) reported that DAB-Am8 and DAB-Am16 dendrimers
as well as their corresponding dendriplexes induce gene expression changes
in human epidermoid carcinoma A431 and human adenocarcinomic alveolar
basal epithelial A549 cells. The cells were exposed to 20 µgml−1 dendrimer
for 4 h, washed and allowed to recover for further 20 h. Changes following
DAB-Am16 treatment with a non-toxic concentration were much more
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profound than those after DAB-Am8 exposure, and dendriplexes induced
less changes than the corresponding dendrimers alone. Furthermore, the
profile of the gene expression changes was strongly cell line dependent.
However, the authors derive from the data that mainly the expression of
genes involved in cytokine signalling, apoptosis, cell cycle, DNA damage and
DNA repair was altered. In particular, in both cell lines and after treatment
with any of the dendrimers or dendriplexes proteasome α4 is upregulated
(although not always significantly). Proteasome α4, also known as PA200,
mediates repair of DNA double strand breaks and was found to facilitate
tumour cell survival after IR-exposure (Blickwedehl et al. 2012; Ustrell et al.
2002). Several genes involved in G1 phase cell cycle progression are also
affected, indicating that the observed effect of DAB-Am16 onto the cell
cycle of cancer cells might be due to gene expression changes rather than to
direct DNA damage. This is further confirmed by the fact that according
to Omidi et al. the COMET assay did not show any DNA damage. They
conclude that on the one hand, the observed alteration of cytokine signalling
by PPI dendrimers supports the suggestion of Moroson that PPI dendrimers
exert their anti-tumour activity via modulation of the immune system. On
the other hand, Omidi et al. argue that a direct effect of the dendrimers
against tumour cells by modification of apoptotic pathway as well as other
genes that are necessary for cell growth and survival is conceivable. As it
has been also shown that PAMAM dendrimers induce pore formation in the
mitochondrial membrane and thus trigger the intrinsic apoptotic pathway
(Lee et al. 2009), PPI dendrimers could elicit the same effect due to their
similar molecular architecture and physico-chemical properties. As a matter
of fact, Kuo et al. (2007) observed an effect of PPI dendrimers on reactive
oxygen species generation and mitochondrial membrane potential of human
U-937 macrophages and suggest the interaction of PPI dendrimers with the
mitochondrial membrane of the cells.
Further investigation of the cytotoxic effect of DAB-Am16 requires a
detailed elucidation of pathways that might contribute to DAB-Am16
mechanism of action. The following three sections give a short introduction
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into the role of some key players of cell cycle regulation and apoptosis that
have been investigated in the context of DAB-Am16 effect on cancer cells.
1.3 Key players of cell cycle progression, DNA damage
and cell death
1.3.1 Role of cyclin D and of histone H3 phosphorylation within the
cell cycle
The cell cycle is a sequence of events in the “life” of a cell that is roughly
divided into four phases: G1, S, G2 and M. G1 and G2 are gap phases in
which cell growth and control of genome integrity occur. DNA replication
takes place within the S phase, while the M phase is the phase of cell
division into two daughter cells. Regulation of the cell cycle is a complex
process and a lot of questions remain unanswered on this issue. Mainly,
the cell cycle is regulated by cyclins and cyclin-dependent kinases (Cdk)
(Malumbres and Barbacid 2005; Malumbres, Harlow et al. 2009; Sánchez
et al. 2005). Currently, 11 Cdk’s (Cdk1–Cdk11) are known that can
differentially associate with 9 cyclins (A, B, C, D, E, F, G, H and L). More
Cdk-like and cyclin-box domain containing proteins have been identified,
but the function of many of them remains obscure. Association of a
particular Cdk with a particular cyclin promotes progression of the cell
cycle at distinct times. Some of the functions of some Cdk/cyclin complexes
are partly redundant, allowing cell cycle progression in the absence of the
particular complex but with altered kinetics and with phenotypic changes
(Malumbres and Barbacid 2005).
Cyclin D1 is an essential protein for cell cycle transition from G1 to
S phase and is characterised as being a proto-oncogene (Bates et al. 1995).
Cyclin D1 associates with Cdk4/6, enabling phosphorylation of retino-
blastoma protein (Rb) (Fig. 7 on the following page). The phosphorylated
Rb releases E2F transcription factors and allows the cell to proceed from
G1 to S phase. Once the cell has entered the S phase, the level of Cyclin D1
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Fig. 7: The role of cyclin D1 in G1/S phase transition. Taken from Coller
(2007).
drops and remains low until the beginning of G2 (Hitomi et al. 1999). How-
ever, cyclin D1 is deregulated in a range of cancers, facilitating uncontrolled
growth and division of tumour cells (Alao 2007; Biliran et al. 2005; Chung
2004; Gautschi et al. 2007; S. Jain et al. 2004; E. S. Kim et al. 2011).
Having completed DNA replication in the S phase, cells pass into G2.
Cell growth proceeds and genome integrity is verified before mitosis starts.
At the beginning of mitosis, chromatin undergoes condensation. The G2/M
checkpoint detects DNA damage and causes cell cycle arrest in G2 and DNA
repair. It is regulated by the p38 kinase (Bulavin et al. 2001; Dmitrieva
et al. 2002).
During mitosis, the nuclear chromosome condenses. This condensation
is accompanied by phosphorylation of histone H3 at serine 10 (Hans et al.
2001). The phosphorylation starts at late G2, is completed in late prophase
and is maintained until early anaphase. The dephosphorylation is completed
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Fig. 8: The DNA damage pathway of mammalian cells. See text for details.
at early telophase (Hendzel et al. 1997). Thus, phosphorylation of histone
H3 at serine 10 can serve as a specific marker for mitotic cells.
1.3.2 DNA damage sensing pathway
S phase arrest can be caused by triggering the S phase checkpoint of the
cell. In fact, there are three different checkpoints within the S phase: the
replication checkpoint, the S-M checkpoint and the intra-S-phase checkpoint
(Bartek et al. 2004). While the intra-S-phase checkpoint is activated by DNA
double-strand breaks (DSBs), the replication and the S-M checkpoint are
elicited in response to problems with DNA replication, e.g. stalled replication
forks. Unlike the G1 and G2 checkpoints, the S phase checkpoints do not
arrest the cell cycle but slow down the progress through the S phase. Fig. 8
shows the main pathways that are involved in S phase checkpoints. The two
serine/threonine kinases ataxia telangiectasia mutated (ATM) and ATM
and Rad3-related (ATR) play a central role in slowing down DNA synthesis
after exposure to genotoxic stress. Cells from ataxia telangiectasia patients
lack ATM and show radioresistant DNA synthesis (RDA).
The classic conception of the cell response to DNA damaging agents
distinguishes between double-strand breaks (e.g. due to ionizing radiation
41
1 Introduction
or radiomimetic drugs) and DNA replication problems (e.g. due to dNTP-
depletion after hydroxyurea treatment or DNA polymerase inhibition by
aphidicolin). Double-strand breaks are thought to activate ATM, which
in turn activates the serine/threonine kinase CHK2, p53 binding protein 1
(53BP1), Nijmegen breakage syndrome 1 (NBS1), breast cancer 1, early
onset (BRCA1) and others. CHK2 then phosphorylates CDC25A at three
sites (S123, S178 and S292) (Soerensen et al. 2003) which leads to ubiquitin-
dependent degradation of this molecule. When unphosphorylated, CDC25A
activates CDK2 interaction with Cyclin A and thus promotes S phase
progression.
On the other hand, impairment of DNA replication is thought to activate
ATR. This in turn activates the kinase CHK1 that phosphorylates the
protein tyrosine phosphatase CDC25A at four different sites (S123, S178,
S278 and S292). At this point, the ATM- and ATR-mediated pathways
converge as these phosphorylations again lead to CDC25A degradation and
S phase progression delay.
However, the discrimination between these two pathways is not as straight-
forward as it seems at first view. The finding that ATR-deficient but ATM-
positive cells also display RDS suggests that ATR is also activated due
to DSBs. This assumption is supported by the observation that although
in ATR-deficient cells exposed to ionising radiation (IR) an immediate
slowdown of DNA synthesis (fast response) occurs to the same extent as in
wild-type cells, the maintenance of the DNA synthesis delay (slow response)
is abolished in cells without ATR (X.-Y. Zhou et al. 2002). On the other
hand, the slow response can be observed in ATM-deficient cells. X.-Y. Zhou
et al. conclude that while ATM leads to increased CDC25A degradation
via CHK2 immediately in response to IR and thus provides a fast response,
ATR is also activated by IR and leads to a delayed CDC25A degradation
via CHK1.
Interestingly, Soerensen et al. (2003) report that ATR is constantly
activated in wild-type cells and induces CDC25A degradation at a basal
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level. However, the IR-induced phosphorylation of CHK1 at S317 and S345
as well as the resulting CDC25A degradation are ATM-dependent.
1.3.3 Pathways of cell death
On the molecular level, two basic pathways of cell death can be distinguished:
apoptosis and necrosis. Apoptosis is a tightly controlled sequence of events
that occurs in response to intrinsic or extrinsic stimuli. The key players of
this process are cysteine-aspartic acid proteases (caspases) that transmit the
death signal, multiply it and activate other proteins that eventually lead to
cell death (Hengartner 2000; Taylor et al. 2008). The caspases can be divided
into initiator and effector caspases. Initiator caspases are activated via
CARD (caspase activation and recruitment domain) or DED (death effector
domain). The binding of these domains to their corresponding domains on
other molecules causes clustering and transactivation of initiator caspases.
Subsequently, they cleave the inactive pro-forms of effector caspases which
in turn leads to activation of molecules that execute the apoptotic process.
Different initiator caspases are activated in response to extracellular (e.g.
binding to receptors of the TNF-R family) or intracellular (e.g. nutrient
deprivation, cell cycle disturbance) stimuli. However, eventually both
pathways converge. One of the most important effector caspases that
is involved in both pathways is caspase-3 that cleaves a wide range of
substrates that initiate the apoptotic cell death. Aside from and due to
caspase activation, there are several other detectable hallmarks of apoptosis.
One of the first events of the intrinsic apoptotic pathway cascade that leads
to downstream initiator caspase (caspase-9) activation is pore formation
in the mitochondrial membrane. This results in leakage of intermembrane
content, particularly cytochrome c and different pro-apoptotic molecules.
Cytochrome c together with Apaf-1 and pro-caspase 9 builds up the seven-
fold symmetric apoptosome that leads to caspase-9 and subsequent caspase-3
activation. The loss of cytochrome c and decreased H+ export after outer
mitochondrial membrane disruption decrease ATP synthesis and also lead
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to membrane depolarization. Thus, one of the early apoptotic events is the
caspase-independent drop of mitochondrial membrane potential (Duessmann
et al. 2003). After caspase-3 and other effector caspases are activated, they in
turn cleave a range of cellular substrates to their active forms. Among others,
this leads to the activation of the caspase-activated DNase (CAD) that
fragments the nuclear DNA between nucleosomes into multiples of approx.
180 bp. Another indicator of apoptosis is the exposure of phosphatidylserine
(PS) on the outer membrane leaflet of the cell. The mechanism of PS
externalization is not well understood. While the general caspase inhibitor
zVAD prevents PS exposure in several cell lines committed to the extrinsic
apoptotic pathway (Martin et al. 1996; Vanags et al. 1996), PS exposure in
primary T lymphocytes during apoptosis is caspase-independent and occurs
simultaneously with the loss of mitochondrial potential (Ferraro-Peyret
et al. 2002).
Besides apoptosis, another major type of cell death exists: necrosis. In the
context of a multicellular organism, programmed cell death (e.g. sculpting
of structures during development) occurs as apoptosis. Apoptotic cells do
not cause inflammation as they do not burst and do not release the cell
content. Instead, they are phagocytosed by macrophages or neighbouring
cells. However, in response to certain toxins, cells can also undergo oncosis
which is characterised by swelling, early cell membrane disruption and
release of cytoplasmic content including factors that cause inflammation.
Cells committed to apoptosis undergo secondary oncosis at a late stage.
However, some studies suggest that apoptosis and necrosis might share
some important pathway members and that the choice of the cell death
pathway does not solely depend on the character of the elicitor but also
on its concentration and on the cell cycle phase of the treated cell at the
moment of addition of the cytotoxic agent to the surrounding environment
(Bonfoco et al. 1995; Hirsch et al. 1997; Yeung et al. 1999).
It has been suggested that autophagy is yet another form of (programmed)
cell death (Tsujimoto et al. 2005). It is based on the engulfment of intra-
cellular components into cytoplasmic vesicles, followed by their digestion
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in lysosomes. Although the existence of this process is considered to be
certain, the precise function of autophagy remains a matter of discussion.
While clearly uncontrolled autophagy will eventually lead to cell death, it
is unknown if regulated autophagy is not actually a survival mechanism in
dying cells (Tsujimoto et al. 2005).
1.4 Problem statement and experimental strategy
After the discovery of the intrinsic anti-tumour effect and favourable toxicity
profile of DAB-Am16 by Dufes et al. (2005), the question about the mechan-
ism of action of DAB-Am16 became particularly important. Understanding
of this mechanism is crucial for exploitation of the tumouricidal properties
of this dendrimer in clinical settings. The aim of this thesis is to contribute
to this understanding.
Two main in vitro effects of DAB-Am16 have been already known: tight
binding to nucleic acids and formation of holes in lipid bilayers. Thus,
three hypotheses arise from this knowledge. First, the dendrimer might
damage the cell membrane in such a way that the cell loses the capability
to retain its cytoplasmic content and to fix the holes, resulting in a necrotic
cell death. The second hypothesis is that once within the cell, DAB-Am16
might enter the nucleus, interact with the nuclear DNA and lead either to
its damage or to the incapability of DNA replication in the course of cell
cycling. This might eventually lead to apoptotic cell death if the cell fails to
circumvent the problem. Yet another possibility is that DAB-Am16 damages
the mitochondrial membrane or membranes of other cellular organelles.
However, this last possibility was not investigated within this project.
To investigate the first two hypotheses, DAB-Am16 was first chemically
characterised to ensure its purity and stability. Then, overall cytotoxic and
cytostatic effects were examined (Fig. 9 on the next page). This allowed
to determine the concentration ranges and incubation times for further,
more detailed experiments. It also led to first observations on how the
dendrimer acts on a range of cancer cell lines. Once concentrations and time
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Fig. 9: Experimental approach to investigation of the mechanism of action
of DAB-Am16.
frames were determined, the hypothesis that DAB-Am16 might derange the
cell cycle was tested by observing the cell cycle profiles upon DAB-Am16
treatment. Subsequently, the mode of cell death was investigated, which
allowed to draw conclusions on its mechanism, since hole formation in the
cell membrane as cause of cell death would be expected to trigger necrosis,
while DNA damage more probably would lead to apoptosis. Finally, effect
on growth of MiaPaCa-2 xenografts in mice, on cell cycle and proliferation
of the tumour cells in vivo was examined and the results were compared
with the in vitro observations.
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2 Materials and Methods
2.1 DAB-Am16 dendrimer
The dendrimer was purchased from SyMO-Chem BV (Eindhoven, The
Netherlands). Three different vials (“batches”) are available. Batch 1 has
been opened for approx. 2 years and used for a number of experiments.
Batch 2 was purchased together with batch 1, but was opened only in
January 2010. Batch 3 was purchased in December 2009. All three batches
have the same lot number 16AM-915651. The dendrimer was stored at 4 °C
in opaque screw-topped glass bottles with a capacity enough for storage of
approx. 30 g of DAB-Am16 each.
2.2 Analytical characterisation
2.2.1 NMR spectroscopy for structure determination and purity
analysis of DAB-Am16
NMR spectra were acquired using Bruker Avance spectrometer equipped
with 5mm BBO probe including Z-axis pulse field gradients operating at
nominal 1H frequency of 400MHz and 13C frequency at 100MHz. All spectra
were processed using Spinworks 3. Chemical shifts were referenced to the
residual CHCl3 signal at 7.26 ppm (1H). The parameters of the experiment
setup were: acquisition time 3.95, 128K time domain and relaxation delay
of 2 s, sweep width of 20 ppm for 1H and 220 ppm for 13C, number of scans
of 32 for 1H, 8 for 1H COSY and 1024 for 13C. The dendrimer was measured
in CDCl3 at a concentration of 50mg/ml.
2.2.2 Mass spectrometry and tandem mass spectrometry analysis of
DAB-Am16 with electrospray ionisation
Further to NMR analysis, samples of the dendrimer from all three batches
have been analysed by mass spectrometry (MS). Samples were dissolved at
a concentration of 5ng/µl in acetonitrile:water (1:1, v/v) with 0.1% formic
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acid. The spectrum was recorded with a quadrupole ion trap mass spec-
trometer (Thermo LCQ Finnigan) equipped with a nano-electrospray ion
source and a Harvard Apparatus syringe pump. Sample was injected manu-
ally through the syringe pump and automatically by a direct injection using
an Ultimate autosampler (Dionex, UK) coupled to the mass spectrometer.
The flow rate of 0.8µl/min was used in both experiments. The positive
nano-electrospray mass spectra were acquired. The instrument operated
using the following settings: spray voltage 1.9 kV, capillary temperature
200 °C, no sheath or auxiliary gas used. The m/z range from m/z 50–2000
was scanned, centroid data was collected. Other conditions were optimised
automatically using the autotune function on DAB-Am16 at a concentration
of 1ng/µl. Data were collected either manually or automatically. Manual
acquisition was performed to record MS and MS2 spectra. MS2 experiment
was performed on a precursor ion, [M]+. For acquisition of MS2 spectra, the
collision energy was set at 35%. The MS2 isolation width was set at 2.00,
so as to allow the selection of precursor ion. MS, MS2 scans consisted of
three averaged “microscans” each with a maximum injection time of 200ms.
An automated program was set-up based on these acquisitions. Data was
collected with the Xcalibur software (ThermoFinnigan).
2.2.3 Matrix-assisted laser desorption/ionisation-time of flight
spectrometry for purity analysis
Spectra recorded with electrospray ionisation revealed some loss of dendri-
mer branches (section 3.1.2). This might occur due to in-source fragmenta-
tion of the molecule during the ionisation procedure as well as being present
in the original sample. To scrutinise this issue further, matrix-assisted laser
desorption/ionisation (MALDI)-time of flight (TOF) spectrometry was used
as another technique of mass spectrometry analysis as this method provides
a softer ionisation procedure and thus is preferred for molecules that can
fragment easily with other techniques, particularly large molecules such as
polymers and particularly dendrimers.
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Additionally, this technique allows detection of possible high molecular
contaminants. Briefly, the dendrimer was dissolved at a concentration
of 0.25µg/ml in methanol. One microlitre of sample was diluted in 20µl
of matrix solution (α-cyano-4-hydroxycinnamic acid 20mg/ml in meth-
anol). Sample (0.5µl) was spotted on to the MALDI target plate. The
samples were allowed to dry in air. MALDI spectra were recorded on an
Applied Biosystems (Framingham, MA, USA) Voyager TOF mass spec-
trometer equipped with a nitrogen laser (337 nm). MALDI spectra were
acquired in the positive-ion mode and were averages of 50 individual laser
shots. The accelerating voltage was set at 20 kV, the focusing guide wire
was at 0.01% and the extraction delay time was 250 ns. Spectra were
externally calibrated using a manufacture calibration mixture containing
Angiotensin I (1.5 pmol/µl), ACTH (1-17 clip) (1.5pmolµl), ACTH (18-39
clip) (2.0 pmol/µl), ACTH (7-38 clip) (3.0pmol/µl), and bovine insulin
(3.5pmol/µl).
2.2.4 Elemental analysis of DAB-Am16 dendrimer
To further confirm the purity of the dendrimer, the weight percent of carbon,
hydrogen and nitrogen in the sample was measured (CHN analysis). This
is accomplished by dynamic flash combustion of the sample in presence of
excess oxygen and determination of the amount of water, carbon dioxide
and molecular nitrogen that arise from the combustion (Harris 1995).
CHN analysis was done with the Carlo-Erba EA 1108 device with PC
based data system Eager 200 for Windows, and a Sartorius Ultra Micro
Balance 4504MP8.
2.3 Stability studies of DAB-Am16
To test the short term stability of dendrimer solutions stored under various
conditions, DAB-Am16 was dissolved in 1ml purified water at a concentra-
tion of 3mg/ml by vigorously vortexing it until it was completely dissolved
and stored either at –50 °C, at 4 °C, at room temperature (RT) or at 37 °C
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in 2ml microtubes (Eppendorf). MALDI-TOF analysis was performed after
24 h and after 6 days according to the procedure described in section 2.2.3.
2.4 Assessment of anti-proliferative effects of
DAB-Am16
Several methods were applied to investigate the cytotoxic and cytostatic
properties of DAB-Am16.
2.4.1 MTT assay
The MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
assay is a colorimetric cytotoxicity assay. MTT is a yellow, water-soluble
tetrazole salt that is reduced to purple, water-insoluble formazan crystals
by metabolically active cells. The absorbance of the formazan produced by
the cells can be measured with a spectrophotometer at 500–600 nm after
dissolving the formazan crystals in DMSO (Mosmann 1983). The conversion
of the tetrazole to formazan was originally supposed to be confined to
mitochondria, being carried out by the enzyme succinate dehydrogenase in
mitochondrial Complex II. However, newer research suggests that the largest
part of MTT reduction is NADH- and NADPH-dependent and involves
enzymes of the endoplasmic reticulum (Bernas et al. 2002; Berridge and
A. S. Tan 1993). In particular, MTT reduction is thought to be correlated
with the glycolysis rate of the cells (Berridge, A. S. Tan et al. 1996).
The MTT reagent (Thiazolyl Blue tetrazolium bromide) was purchased
from Alfa Aesar (Ward Hill, MA, USA). Cells were seeded at 500 cells
per well in 96-well plates. They were allowed to grow for three days and
then treated with DAB-Am16 (Sigma Aldrich) at indicated concentrations
(200µl per well) for either 4 or 24 h. Subsequently, cells were washed with
Dulbecco’s phosphate-buffered saline (DPBS, Invitrogen) and incubated for
another 48 h with normal medium. Medium was discarded, cells washed with
DPBS and 100 µl MTT solution (50µgml−1) added. Cells were incubated
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with the MTT solution for 2 h at 37°C, medium was removed accurately,
100 µl DMSO (Sigma Aldrich) added. After an incubation for 10min at
37°C the absorbance at 570 nm was measured.
For analysis, background values were substracted. The cytotoxicity was
determined as the ratio between the measured absorbance value of treated
and untreated cells. Lysed cells (with Triton X-100 (Sigma Aldrich)) were
used as a control for 100% effect. All experiments were performed thrice,
with six repeats per experiment. The 18 values were pooled and the overall
mean was calculated.
2.4.2 LDH assay
Rapid onset of severe cytotoxicity can be monitored by detection of the
release of cytoplasmic enzymes into the surrounding medium. This principle
underlies the lactate dehydrogenase (LDH) assay that is based on color-
imetric detection of LDH release (Korzeniewski et al. 1983). Within the
cell, LDH converts lactate to pyruvate and thus is an essential component
of glycolysis that is present in the cytosol of all mammalian cells. If the
cell membrane becomes severely disrupted during necrosis or late stage
apoptosis, LDH leaks out of the cell. For detection, the supernatant of
treated cells is removed and the reaction mix is added. Within the reaction
mix, lactate is oxidised to pyruvate by LDH upon reduction of NAD+ to
NADH. This NADH in turn is necessary for conversion of the tetrazole INT
(2-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenyl tetrazolium chloride) to form-
azan by the enzyme diaphorase, as illustrated in Fig. 10 on the following
page. The absorption of the solution at 490 nm can be used to quantify the
formazan and thus to assess plasma membrane integrity of the cells.
The CytoTox® 96 nonradioactive cytotoxicity assay (Promega Corpora-
tion, Madison, WI, USA) was used to quantitatively measure LDH. Cells
were seeded at 500 cells per well in 96-well plates, grown for three days,
treated with DAB-Am16 at indicated concentrations for the indicated peri-
ods of time and LDH released into the surrounding medium was determined
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Fig. 10: Scheme of the LDH assay (CytoScan™ LDH Cytotoxicity Assay).
according to the manufacturer’s instructions. Briefly, 50µl supernatant
were collected from each well, 50µl reconstituted substrate mix were added,
the samples were incubated for 30min at room temperature before addition
of stop solution (50 µl per well) and absorbance measurement at 490 nm.
For analysis, background values were substracted from the measured
values and cell viability expressed as the ratio between the LDH release
of treated cells and the LDH release of untreated control cells that were
lysed 45min before sampling (maximum LDH release). Experiments were
performed in triplicates.
2.4.3 Colony formation assay
The colony formation or clonogenic cell survival assay tests the ability of
single cells to divide and build colonies (Munshi et al. 2005). Formation of
clonogenic colonies from single cells was investigated as early as in the 1950’s
with the minimum cell number per colony that allows further propagation
being 25–50 cells (Puck et al. 1955). Since then, the ability to form colonies
has been used as a method to test the loss of unlimited proliferative ability
in cancer cells upon treatment with different cytotoxic drugs or irradiation
in vitro (Bird et al. 1987; Franken et al. 2006; Roper et al. 1976; Twentyman
et al. 1984). After the desired treatment, cells were collected, counted and
200 viable cells were seeded per well of 6-well plates in supplemented cell
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Fig. 11: General operating principle of a flow cytometer. As single cells
pass through a laser beam, their fluorescence emission and the extent of
light diffraction are recorded. Source: Semrock. Inc. (Filters for Flow
Cytometry)
culture medium. After 7–10 days distinct colonies became visible under
the microscope. Medium was removed, cells were carefully washed with
PBS and the colonies were fixed and stained by 5min incubation with 2ml
per well staining solution (0.5% crystal violet in methanol). The solution
was removed and the wells carefully washed with water. The plates were
air-dried over night, pictures were taken of the wells and quantification was
performed with ImageJ using a size-cutoff that corresponds approximately
to a minimum of 50 cells per colony.
2.5 Flow cytometry
Flow cytometry is a method that has been widely used within the experi-
mental work presented in this dissertation. For a better understanding of
the figures that depict the results of flow cytometric experiments, a brief
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Table 1: Excitation and detection channels of MACSQuant Analyzer.
Excitation Channel Emission filters Detection Fluorochromes
wavelength range (nm)
405 nm FL1 450/50 425–475 DAPI, MMC
488 nm FL2 525/50 500–550 FITC, PhiPhiLux
FL3 585/40 565–605 TMRE
FL4 655 (LP) + 655–730 PI
730 (LP DM)
FL5 750 (LP) 750–
635 nm FL6 655 (LP) + 655–730
730 (LP DM)
FL7 750 (LP) 750–
488 nm FSC/SSC 488/10 483–493 Light scatter
introduction into this method and data analysis techniques follows. This
summary is based on Ormerod (2009); Shapiro (2003); Watson (1992).
A flow cytometer measures the light scatter and the fluorescence of
single cells within a cell sample (Fig. 11 on the previous page). The
flow cytometer that this work was performed with is the MACSQuant
Analyzer from Miltenyi Biotec (Bergisch Gladbach, Germany) equipped
with three lasers emitting light with 405, 488 and 635 nm wavelength,
respectively. MACSQuant allows the simultenous measurement of up to
7 colours emitted by fluorescent probes by providing 7 emission filters.
Additionally, the forward and the right angle (side) scatter can be measured.
Table 1 summarizes the features of the channels within the MACSQuant
Analyzer and lists the fluorochromes that were used for this thesis according
to the channel they were measured in. Long pass (LP) filters only let pass
higher wavelength, while a long pass dichroic mirror (LP DM) reflects all
wavelengths that are higher than its specified wavelength.
There are several ways to present data obtained by flow cytometry. A
histogram reflects the distribution of the recorded fluorescence intensity
of the cell population for a single parameter, i.e. within one fluorescence
channel. The fluorescence intensity is shown on the x-axis, while the number
of cells emitting this fluorescence intensity is represented on the y-axis.
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Examples of histograms can be seen in Figure 24 on page 84. When several
samples (e.g. differently treated cells) are to be compared, their fluorescence
intensity distributions can be overlayed within one histogram. However, if
different cell numbers were recorded for these samples, the histogram has
to be normalised to the area of the curve to allow accurate comparison. For
an example see Figure 26 on page 86.
One of the main strengths of flow cytometry is the ability for multicolour
detection, i.e. for every single cells up to 7 colours can be simultaneously
detected with MACSQuant (and even more with some other machines),
thus allowing to distinguish populations according to several parameters.
The MACSQuantify software allows data presentation as two-dimensional
plots where each axis corresponds to another fluorescence channel. Every
single cell is depicted as a dot within a two-dimensional dot plot so that the
correlation of two different parameters can be characterised (e.g. Figure 29
on page 91 right plot in the top row and both plots in the bottom row).
Such two-parameter plots are also called cytograms.
A density plot is another form of a cytogram and can be a more intuitive
way for identification of separate subpopulations. Areas with the highest
density of cells are depicted red, those with less cells yellow, less dense areas
are green and within areas with a low cell density each cell is represented
by a blue dot. For an example see Figure 27 on page 88.
For data analysis, it can be desirable to focus on one particular sub-
population, e.g. to quantify the apoptotic cell subpopulation within the
measured sample. If more than two parameters were measured, the sub-
populations from one cytogram or histogram can be plotted on new cyto-
grams/histograms with other parameters on the axes. For this purpose, the
user can draw a region around the population of interest. This drawing
is called a gate (e.g. the red gate in Figure 27 on page 88). An unlimited
number of gates can be set for each sample, and each gate is designated
a name and a colour. Statistical analysis can be performed separately on
populations within different gates. It is also possible to plot a population
within a gate on a new plot or histogram and to set further subgates which
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leads to a nested gate hierarchy. To find out where a gated subpopulation
is located on a plot of the whole population or another subpopulation
regarding its parameters, it can be depicted on a dot plot in a distinct
colour (e.g. the violet subpopulation in Figure 35 on page 96 in the right
column against the background of the whole population depicted in black).
In addition to the detection of fluorescence intensities, a measurement
with a flow cytometry also gives information about the light scattering
properties of the cells. The forward scatter (FSC) is a measure for how
much light is scattered in the forward direction while the side scatter (SSC)
detects the scattering of light to the right angle of the laser beam (e.g. left
column in Figure 33 on page 95). Generally speaking, forward scatter is
regarded as a mean to estimate the size of a cell relative to the other cells
within the sample, while side scatter correlates with the granularity and
shape of the cell.
In a usual flow cytometry experiment, at least 10,000 events are recorded.
A large limitation of conventional flow cytometry is the limited number
of fluorophores that can be detected per cell. This is due to the overlap
of emission spectra of the fluorophores. Although the amount of the
overlap can be measured with single-stained control samples and then
automatically substracted from the measured values by the machine, the
emission spectra of simultaneously measured dyes should still be reasonably
separated. Another disadvantage of flow cytometry is the inability to
simultaneously visualise cell morphology and the fluorescence distribution
within the cell. Despite these limitations, flow cytometry is a very powerful
and versatile tool for elucidation of cellular pathways.
2.6 DNA quantification
To assess the effect of DAB-Am16 on the cell cycle, quantitative staining of
DNA was performed with propidium iodide.
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2.6.1 Propidium iodide staining
Propidium iodide (PI) is a DNA intercalating dye that has been extensively
used for cell cycle profiling since the late sixties of the previous century
(Crissman, Orlicky et al. 1979; Crissman and Steinkamp 1973; Dengler et al.
1995; Fried et al. 1976; Hudson et al. 1969; Krishan 1975; Mazzini et al.
1983; Waring 1970). It has an excitation range of approximately 450–600 nm
and a broad emission spectrum of about 550 to more than 700 nm (Product
Spectra - Propidium iodide/DNA). In this project, the excitation wavelength
488 nm and an emission filter of 655–730 nm (655 (LP)+ 730 (LP DM)) was
used. Cells were harvested by trypsinization keeping the original medium,
as apoptotic cells become especially buoyant and might be discarded with
the medium. Subsequently, cells were washed with phosphate buffered
saline (PBS), the pellet was loosened by gently tapping the vial, ice-cold
70% ethanol was added while vortexing to prevent cell clumping and cells
were incubated with the ethanol for at least 30min at 4 °C. Cells were
then washed with PBS and RNA was digested by 15min incubation with
50µl RNase A (100 µg/ml) at room temperature. PI (50 µg/ml, 250µl) was
added to the sample for an incubation time of 30min at room temperature
prior to measurement with the MACSQuant flow cytometer. Fluorescence
was recorded on a linear scale and the cell cycle profile was displayed as a
fluorescence histogram.
2.6.2 BrdU staining
5-bromo-2’-deoxyuridine (BrdU) is a thymidine analogue that can be incor-
porated into DNA during its synthesis. After incorporation, BrdU can be
detected with an antibody by flow cytometry (Dean et al. 1984; Dolbeare
et al. 1983; Gratzner 1982; Gratzner and Leif 1981; Gratzner, Leif et al.
1975). In this experiment, 10µM BrdU in PBS was added to the cell culture
30min before harvesting and washing the cells. After 30min fixation with
70% ethanol at 4 °C, cells were washed twice with PBS and resuspended in
500µl hydrochloric acid for 30min at room temperature. Acid was then
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spinned off and the cells washed twice with PBS and once with PBS-T
(PBS + 0.1% BSA + 0.2% Tween 20). 20µl mouse monoclonal anti-BrdU
antibody (BD Biosciences, 347580) were added directly to the cell pellet
for 20min at room temperature. Cells were washed once with PBS-T and
incubated with 5µl polyclonal FITC-conjugated goat anti-mouse antibody
(BD Biosciences, 554001) for 20min at room tempreature in the dark.
Cells were washed once with PBS and stained with propidium iodide as
described in section 2.6.1. For logarithmic FITC detection, FL2 was used
at MACSQuant [excitation 488 nm, emission filter 525/50 (500–550 nm)].
Simultaneous detection of propidium iodide was performed as described in
section 2.6.1. Compensation between channels FL2 and FL4 was performed
manually.
2.7 Detection of apoptosis and cell proliferation
2.7.1 Mitochondrial potential, cell membrane permeabilisation and
caspase activation
A multifaceted approach was chosen to investigate the mode of cell death
caused by DAB-Am16. Characteristics of cells measured are (Donald
Wlodkowic et al. 2011; D. Wlodkowic et al. 2010):
• Light scattering properties
– Due to cell shrinkage and increased cell granularity apoptotic
cells show a decrease in forward scatter and increase in side
scatter.
• Mitochondrial membrane potential
– The mitochondrial membrane potential drops as the mitochon-
drial permeability transition pore opens.
• Cell membrane integrity
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– Perforation of the cell membrane is the last step of apoptosis
(“secondary necrosis”) that is followed by complete cell disinteg-
ration and death.
• Caspase activation
– Caspase-3 is a key molecule that is activated during apoptosis
and leads to the characteristic apoptotic events within the cell.
• DNA fragmentation
– Caspase-3 activates an endonuclease that cleaves the nuclear
DNA, thus rendering DNA fragments to leave the cell and letting
the cell with a decreased DNA amount that can be seen upon
DNA staining.
The simultaneous measurement of several parameters for each single
cell allows not only to determine the onset of apoptosis, but also the time
course of events. Results showed that signs of apoptosis could be determined
as early as 2 h after addition of DAB-Am16 to the cell culture medium,
indicating a fast onset of cytotoxic effects of the dendrimer.
Cell death is associated with a drop in mitochondrial membrane potential
(∆Ψm) leading to the failure of adenosine triphosphate (ATP) production
(Ly et al. 2003). During apoptosis, ∆Ψm collapses and pro-apoptotic
factors are released from mitochondria. There is a disagreement if these
factors activate caspase-3, or if in turn caspase-3 activation leads to ∆Ψm
and pro-apoptotic factor release. Bossy-Wetzel et al. (1998) showed that
cytochrome c release from mitochondria can occur without a drop of ∆Ψm,
while this drop can take place after caspase-3 activation. Karpinich, Tafani,
Rothman et al. (2002) showed that collapse of ∆Ψm occurs late in the
apoptotic cascade upon etoposide treatment of Jurkat cells. In Jurkat cells
lacking p53 and Bax, Karpinich, Tafani, Schneider et al. (2006) found that
at early time points, cytochrome c release from mitochondria is necessary
for caspase-3 activation. However, at later time points in turn caspase-3
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stimulates mitochondrial cytochrome c release. The pan-caspase inhibitor
ZVAD decreases cytochrome c release as well as overall loss of cell viability
at incubation times of more than 6 h. Thus, there is no generally applicable
order of apoptotic events and ∆Ψm drop can appear both before and
after caspase-3 activation. Ahsen et al. (2000) showed that mitochondrial
cytochrome c release does not necessarily cause depolarisation of the inner
mitochondrial membrane. Similarly, Arnoult et al. (2002) observed that
cytochrome c release triggered by the pro-apoptotic Bcl2 family member
Bax does not lead to the release of the apoptosis-inducing factor AIF. In
some leukemic cell lines, partial reduction of ∆Ψm occurs before caspase-3
activation, but active caspase-3 initiates a feedback loop, triggering com-
plete ∆Ψm collapse and cell death (Marzo et al. 2001). Lakhani et al.
(2006) found that caspases 3 and 7 act upstream of the change of ∆Ψm in
fibroblasts. These findings indicate the time series of caspase activation and
mitochondrial membrane potential collapse is not unequivocal and might
differ between cell lines as well as be dependent on the treatment applied.
To assess the mitochondrial membrane potential, the cationic, lipophilic,
cell-permeant dye Tetramethylrhodamine ethyl ester (TMRE) (Invitrogen,
Paisley) is used. It accumulates and fluoresces in mitochondria depending
on the mitochondrial membrane potential ∆Ψm, so TMRE-positive cells
are those with an intact mitochondrial membrane potential, while cells with
a collapsed ∆Ψm appear TMRE-negative (Scaduto et al. 1999).
For determination of cell membrane integrity, the capability of the non-
cell permeant DNA dye DAPI (Sigma Aldrich, St. Louis) to enter the cell
after DAB-Am16 treatment is measured. Those cells that have an intact
cell membrane do not exhibit DAPI fluorescence, as DAPI cannot cross an
unperforated cell membrane. On the other hand, cells with holes in the
plasma membrane are readily entered by DAPI (Donnenberg et al. 2007).
Within the cell, DAPI binds to DNA and exhibits blue fluorescence.
Caspase-3 activation was tested with the cell-permeant caspase-3 sub-
strate PhiPhiLux G1D2 (OncoImmunin Inc., Gaithersburg). This fluoro-
genic substrate contains the amino acid sequence DEVDGI that is recognised
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by active caspase-3. Upon clevage by the active caspase-3, the substrate
emits green fluorescence which can be detected by flow cytometry (Telford
et al. 2004).
After DAB-Am16-treatment cells were incubated with 100 nM (TMRE)
for 30min, harvested and centrifuged. Medium was removed completely and
40µl PhiPhiLux G1D2 were added to the pellet. The pellet was carefully
dissolved in this PhiPhiLux solution and cells were incubated for 1 h at
37 °C. Cells were then washed once with PBS and dissolved in 200µl PBS
with 5 µl DAPI (200µg/ml) per sample. DAPI fluorescence was detected in
FL1, PhiPhiLux G1D2 in FL2 and TMRE in FL3, all of them on logarithmic
scale. Compensation was carried out with single-stained cells.
2.7.2 EdU and histone H3 detection
5-ethynyl-2’-deoxyuridine (EdU) is a thymidine analogue that is used for
the same purpose as BrdU. The advantage of EdU compared to BrdU is
its easy detection by click chemistry that leads to the copper-catalysed
formation of a covalent bond between the alkyne EdU and the azide Alexa
Fluor 647 that makes the acidic denaturation of the cellular DNA obsolete
(Buck et al. 2008). This in turn allows to combine EdU-staining with the
staining with different antibodies.
Cells were incubated with 10µM EdU (Invitrogen, Paisley) for 30min,
harvested and washed once with PBS. 100 µl 4% paraformaldehyde were
added to the pellet and cells were fixed for 15min at room temperature
in the dark. Cells were then washed once with washing buffer (1% BSA
in PBS) and incubated with 0.1% Triton-X 100 in PBS for 10min at
room temperature. Cells were then washed once with washing buffer and
the supernatant was completely removed after centrifugation. The click
reaction cocktail with Alexa Fluor 647 was freshly prepared according
to the manufacturer’s instruction. The pellet was dissolved in the click
reaction mixture and incubated for 30min at room temperature in the dark.
Cells were washed twice with PBS-T (3% BSA, 0.05% Triton-X 100 in
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PBS) and the supernatant was completely removed after the second wash.
1 µl phospho-Histone H3 (Ser10) (6G3) mouse monoclonal antibody (Cell
Signaling, 9706) was added to the pellet for 1.5 h (room temperature in the
dark). Cells were then washed again with PBS-T which was completely
removed after centrifugation. 5µl FITC polyclonal anti-mouse Ig antibody
(BD Biosciences, 554001) were added for 20min at room temperature in
the dark. The cells were washed once with PBS, and DNA staining with
PI was performed as described in section 2.6.1. FITC was measured in
FL2 (logarithmic scale), PI in FL4 (linear scale) and Alexa Fluor 647 in
FL6 (logarithmic scale). Compensation was performed with single-stained
samples.
2.7.3 Detection of phosphorylated histone H2A.X
Histone 2A.X (H2A.X) is phosphorylated at serine 139 upon occurrence
of stalled replication forks or DNA double-strand breaks (Ewald et al.
2007; Lowndes et al. 2005; Paull et al. 2000; Rogakou et al. 1998). The
phosphorylated H2A.X is also called γ-H2A.X.
Cells were harvested and washed once with PBS. 100µl 4% paraform-
aldehyde were added to the pellet and cells were fixed for 15min at room
temperature in the dark. Paraformaldehyde was spun off and cells were
permeabilised with 0.1% Triton-X 100 for 10min at room temperature.
Cells were then washed twice with blocking buffer (3% BSA, 0.05% Triton-
X 100 in PBS), spun off and the supernatant removed completely. 1µl
phospho-Histone H2A.X (Ser139) (20E3) rabbit monoclonal antibody Alexa
Fluor 488 conjugate (Cell Signaling, 9719) was added to the pellet for 1 h
(room temperature in the dark). The cells were washed once with PBS, and
DNA staining with PI was performed as described in section 2.6.1. Alexa
Fluor 488 was measured in FL2 (logarithmic scale) and PI in FL4 (linear
scale). Compensation was performed with single-stained samples.
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2.8 In vivo evaluation
Female mice (CD1-nu; initial mean weight 20 g) housed in groups of five at
19 °C to 23 °C with a 12-hour light-dark cycle were fed a conventional diet
(Rat and Mouse Standard Expanded, B&K Universal, Grimston, United
Kingdom) with mains water ad libitum. Experimental work was carried
out in accordance with U.K. Home Office regulations and approved by the
local ethics committee.
Tumour cell suspension [MiaPaCa-2 human pancreatic carcinoma (ATCC
CRL-1420)] in exponential growth was injected s.c. (5× 106 cells in 100µl
overall volume consisting of 50 µl DMEM cell culture medium (Invitrogen)
supplemented with 10% Foetal Bovine Serum (Biosera, Miami, USA) and
5mM L-Glutamine (Invitrogen), and 50µl Matrigel (BD Biosciences)) per
flank. Tumours typically reached diameters of 5mm or more within 13
days. Average animal weight was 24.4 ± 1.4 g across all groups and the
whole experimental period. DAB-Am16 in 5% dextrose was administered
to 6 mice intraveneously via the tail vein on days 1, 3, 5, 8, 10, 12, 15 and
17 at 10mg/kg. A negative control group of 6 mice did not receive any
injections. A positive control group of 5 mice was injected with gemcitabine
(Sigma-Aldrich, Dublin, Ireland) in physiological saline (1.7mg per mouse)
on days 1, 4, 7, 11, 14 and 16. Tumour size and weight were recorded by
the same person on every day of DAB-Am16 injection. One day after the
last injection the animals were sacrificed, the tumours removed and cut
in several pieces. One piece was stored on ice in PBS-EDTA (PBS with
0.1% (w/v) EDTA), another two pieces were fixed in 10% formalin for
48 h at 4 °C and then transferred into 70% ethanol for long-term storage at
room temperature, and one piece was immediately frozen in liquid nitrogen
and stored at –80 °C. The piece in PBS-EDTA was dissociated as described
by Heinlein et al. (2010). The tumour tissue was cut in small pieces
and consecutively filtered through a 100µm cell strainer being in contact
with PBS-EDTA in a petri dish and a 35µm filter (BD Biosciences and
Miltenyi Biotec, respectively). The filters were washed with PBS-EDTA
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and the resulting solution was filled up to 10ml. The cells were centrifuged,
the supernatant removed, the pellet resuspended in 0.5ml PBS-EDTA
and fixation was carried out by slowly adding 5ml ice-cold 70% ethanol
while gently vortexing. Cells were then stored at 4 °C for a week. The
DNA staining with propidium iodide and the flow cytometric cell cycle
measurement were performed as described in section 2.6.1.
2.9 Statistical analysis
Statistical analysis was performed with Microcal OriginPro 8. For in vitro
experiments, the standard deviation was used for plotting error bars, while
standard error of the mean was plotted for in vivo data. Significance testing
was performed with One-Way ANOVA using Bonferroni Test for means
comparisons. The significance level tested was 0.05 in all cases. Non-linear
curve fitting for the MTT assay was conducted using a logistic dose-response
model according to the following equation:
y = A1 − A21 + (x/x0)p + A2
EC50 values were then calculated based on this curve fit.
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3 Results
3.1 Analytical characterisation of DAB-Am16
For meaningful experimental results it is crucial to ensure that the dendrimer
used is of highest quality and purity. Another important aspect is the
stability of the dendrimer over time as well as after exposure to different
environmental conditions. To address these issues, a number of analytical
tests have been performed on all three batches described in section 2.1. The
results were compared with data obtained by Chooi (2007) in our group as
well as with published data (Adhiya et al. 2002; Chai et al. 2001; McLuckey
et al. 2000).
Analytical characterisation of DAB-Am16 was performed by nuclear mag-
netic resonance (NMR), mass spectrometry (MS) and elemental analysis.
3.1.1 NMR spectroscopy for structure determination and purity
analysis of DAB-Am16
1H, 13C and COSY NMR were performed for structure identification and
for comparison of three different dendrimer vials that were purchased and
opened at different time points. The latter comparison allows to make a
statement on the stability of the dendrimer during long-term storage.
The 1H NMR spectra obtained from all three samples are shown in
Fig. 13 on page 67. The carbon atoms of the dendrimer have been assigned
consecutive numbers, as illustrated in Fig. 12 on page 69. As the molecule is
symmetric only the enumeration for one branch starting from the core and
ending at one of the 16 outer carbon atoms is shown for a better overview.
Therefore, carbon atoms exist with the same environment, i.e. two atoms
have been assigned number 1, two carbon atoms have the environment
corresponding to number 2, four carbon atoms should be included in the
peak for number 3 and so on. As every carbon atom bears two hydrogen
atoms, the area under the peak for hydrogen atoms at carbon number 1
corresponds to four hydrogen atoms and the same principle applies for all
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Table 2: Expected and the mean measured ratios of peak areas in the 1H
NMR spectra.
Experimental values
Chemical Carbon atom Expected number Vial 1 Vial 2 Vial 3
shift [ppm] numbers of H atoms
1.483 1 4
1.7 4, 7, 10 88 91 92 90
2.5 2, 3, 5, 6, 8, 9 88 91 92 90
2.677 11 32 33 33 31
the other peaks. The peak for the hydrogen atoms for the carbon atoms 4, 7
and 10 overlaps with the hydrogen atoms of the terminal amine groups that
have to be taken into account as well. Using the peak for hydrogen atoms at
carbon 1 as a reference point, the number of hydrogen atoms that build up
the other peaks has been calculated and compared with the expected values.
All these values are shown in table 2 for all three vials. It is evident that
all peaks obtained could be assigned according to the dendrimer structure
and that the difference between empiric and theoretical data is very small
for all peaks which suggests a high purity of the dendrimer used for the
manufacturing. Additionally, the NMR spectroscopy results correspond
very well to the data of Dr Chooi (Fig. 13 on page 68) as well as to the
spectra reported in the literature (Chai et al. 2001).
To further confirm the purity and identity of the dendrimer, 13C and
1H COSY spectra were also recorded. Again, all three vials yielded very
similar results, so only one representative spectrum for each NMR type
is shown in Fig. 14 on page 70. The 13C spectrum corresponds very well
to the literature data (Chai et al. 2001). Also, the quantification of the
experimental data shows a good correlation with exception of C atom 4.
The value for this atom is almost three times higher than the expected one.
A closer look at the peak shape reveals that two peaks seem to have merged
at this point. The identity of the second peak is not clear. However, it is
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(b) Vial 2
Fig. 13: 1H NMR of the three DAB-Am16 vials stored for different time
ranges (continued on the following page)
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(c) Vial 3
Fig. 12: 1H NMR of the three DAB-Am16 vials.
Fig. 13: NMR data from previous experiments, provided by Dr Kar Wai
Chooi.
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Table 3: Expected and the mean measured ratios of peak areas in the 13C
NMR spectrum.
Chemical Carbon atom Expected number Experimental
shift [ppm] numbers of C atoms values (vial 2)
25.090 1 2 2
24.561 4 4 11
30.940 10 16 15
40.740 11 16 16
51.935 9 16 15
52.300 6, 5, 8 20 19
52.563 3 4 4
54.373 2 2 3
conceivable that a small fraction of dendrimers in the sample might have
minor defects and an additional peak arises from this altered structure.
The 2D COSY spectrum shows
Fig. 12: The numbering scheme of C
atoms for the peak assignment of the
NMR spectra.
cross-peaks between the peaks cor-
responding to atoms (11) and (4,
7, 10), (9) and (4, 7, 10), (2, 3, 5,
6, 8) and (4, 7, 10). There is no
coupling between (2, 3, 5, 6, 8) and
(11), (9) and (11), (2, 3, 5, 6, 8)
and (9). Considering the structure
of the molecule (Fig. 12), the results
completely match the expectations.
3.1.2 Mass spectrometry and tandem mass spectrometry analysis of
DAB-Am16 with electrospray ionisation
Again, the spectra of the dendrimers from all three samples show an identical
composition of the vial content. Only the spectrum for vial 2 is shown
in Fig. 15a on page 72. The peak at m/z ratio 1686.6 corresponds to the
molecular ion (precursor ion). The peak at m/z 1629.6 indicates the loss of
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Fig. 14: Representative 13C and COSY spectra.
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a (CH2)3NH2 group (a 3rd generation branch) at the outer shell. A loss of
a second group of the same size explains the peak at m/z 1573.6. When a
second generation branch is lost consisting of (CH2)3N[(CH2)3NH2]2, a peak
at m/z 1515.4 can be seen. Finally, the loss of a whole branch emerging
from a nitrogen atom of the core leads to a mass difference of approx.
400, which results in the peak at m/z 1287.4. The existence of a double-
charged molecular ion leads to the peak at m/z 844.3, the triple-charged
molecular ion corresponds to the peak at m/z 563.5 and the four times
charged molecular ion is seen at m/z 422.9. Some other peaks with very
low intensities are also present in the spectrogram that can be explained
by further fragmentation and ionisation events. The peak at m/z 1748.5
might correspond to an adduct of DAB-Am16 with acetonitrile and sodium
although there is a mass difference of 2 to the expected m/z value which
might be due to proton loss.
Fig. 15b on the following page shows an MS/MS spectrum of the molecular
ion of DAB-Am16. The three main peaks correspond to the results of
intramolecular nucleophilic substitution reactions: from an attack of an
amine group onto the adjacent α-C-atom a quaternary ammonium ion
and a neutral amine arise (Adhiya et al. 2002; McLuckey et al. 2000).
Dependent on the generation layer of the protonated nitrogen different sizes
of fragments appear. The arising quaternary ammonium ions have m/z
ratios of 1555.5, 1327.3 and 870.8 for generation 2, 1 and 0, respectively.
This matches exactly the observed MS/MS spectrum and further confirms
the identity of the sample.
3.1.3 Matrix-assisted laser desorption/ionisation-time of flight
spectrometry for purity analysis
The previously mentioned loss of dendrimer branches in the MS spectra
might occur due to in-source fragmentation of the molecule during the
ionisation procedure as well as being present in the original sample. To
scrutinise this issue further, matrix-assisted laser desorption/ionisation
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(a) Mass spectrometry measurements of a sample of DAB-Am16 from vial
2 with electrospray ionisation (ESI). The peaks are assigned according to
the colour scheme provided on the right of the spectrum.
(b) MS/MS spectrum of the molecular ion of the DAB-Am16 dendrimer.
Fig. 15: Mass spectra of DAB-Am16.
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Fig. 16: MALDI-TOF analysis of the dendrimer from vial 2.
(MALDI)-time of flight (TOF) spectrometry was used as another technique
of mass spectrometry analysis as this method provides a softer ionisation
procedure and thus is preferred for molecules that can fragment easily
with other techniques, particularly large molecules such as polymers and
particularly dendrimers. Additionally, this technique allows detection of
possible high molecular contaminants.
As can be seen in Fig. 16, no high molecular weight contaminants are
observed. The prominent peak at m/z 1687.8 corresponds to the molecular
ion of DAB-Am16, while the two small peaks at m/z 1630.8 and 1572.7
again can be assigned to the loss of one or two (CH2)3NH2 branches. This
can be attributed to the existence of a small percentage of minor defects
that occur during the sequential procedure of dendrimer synthesis. The
peak at m/z 663.5 was also seen after electrospray ionisation and cannot
be explained at the moment. It could be either another fragment of the
dendrimer or a contaminant. However, its intensity is very low, indicating
the high purity of the sample. Similar results were obtained for samples
from all three vials.
3.1.4 Elemental analysis of DAB-Am16 dendrimer
The results are shown in Table 4 on the following page. The minor deviance
between the observed and the expected values especially for the relative
amount of carbon in the sample can be explained by the minor defects that
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Table 4: Elemental analysis of DAB-Am16 dendrimer samples from all
three vials.
Element: C H N
Vial: 1 2 3 1 2 3 1 2 3
59.80 60.84 60.39 11.30 12.33 12.63 22.58 23.94 24.01
59.73 60.85 60.41 11.36 12.48 12.48 22.75 23.89 23.92
60.72 60.74 60.52 12.69 12.48 12.63 24.48 23.81 24.93
60.89 60.78 60.49 12.51 12.51 12.48 24.58 23.91 24.91
Mean: 60.29 60.8 60.45 11.97 12.45 12.56 23.6 23.89 24.44
Overall 60.51 12.32 23.89mean:
Standard 0.26 0.31 0.43deviation:
Expected: 62.66 12.43 24.91
were also seen in the mass spectrum (loss of one or two branches of the 3rd
generation layer).
3.2 Stability studies of DAB-Am16 with MALDI-TOF
Fig. 17 on the next page shows two representative spectra: at room temper-
ature after 1 day and at 37 °C after 6 days. In both spectra, a high peak for
the molecular ion at m/z 1686.7 is observed. The small peaks at m/z 1629.7
and m/z 1514.7 can be attributed to minor defects discussed in section 3.1.2.
The peak at m/z 870.5 has been seen previously in the MS/MS spectrum
as a quaternary ammonium ion emerging from a nucleophilic substitution
reaction. A small peak for a contaminant or another dendrimer fragment is
again seen at m/z 663.5–643.9.
Overall, it is evident from this data that no decomposition of DAB-Am16
dissolved in water occurred even after exposure to 37 °C for 6 days.
3.3 Characterisation of the growth properties of the cell
lines
For the cell lines that have been used for in vitro experiments, growth
curves were recorded in order to estimate the duration of exponential
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(a)
(b)
Fig. 17: MALDI-TOF spectra of DAB-Am16 dissolved in water and stored
at (a) room temperature for one day and (b) 37 °C for 6 days.
growth and the doubling time of the cells. The results are shown in Fig. 18
on the following page. It can be seen from the growth curves that cells in
general need approx. 3 days to adapt after having been seeded (lag-phase)
before they start growing exponentially (log-phase). As a consequence, for
experiments with DAB-Am16, cells were seeded 3 days prior to addition of
the dendrimer to ensure that they were in the log-phase when the dendrimer
started to take effect on them. This is important because a lot of anti-
cancer agents act specifically against fast growing cells that are usually
found in tumours. Assuming that DAB-Am16 might also act on cell growth
and division, the investigation of the precise effects of DAB-Am16 was
performed during the phase of fastest cell growth. The doubling time for
the cell lines was calculated according to the following formula:
T (d) = (t3 − t1)× log(2)
log(Q3/Q1)
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(a) MiaPaCa-2 (b) MDAMB231
(c) U87MG
Fig. 18: Growth curves for MiaPaCa-2, MDAMB231 and U87MG cell lines.
The doubling times are 18 h, 17 h and 30 h, respectively.
3.4 DAB-Am16 exhibits a concentration- and
time-dependent cytotoxic effect
Once the identity and purity of the dendrimer was established, the anti-
proliferative effect of DAB-Am16 was scrutinised. The MTT and LDH
assays were used for the evaluation of the cytotoxicity, while the colony-
formation assay (CFA) was applied to examine the cytostatic effect.
3.4.1 Change of the glycolysis rate upon DAB-Am16 treatment
The results of the MTT assay for several cell lines is depicted in Fig. 19 on
the next page and listed in Table 5 on the following page. The half maximal
effective concentration (EC50) values differ between the cell lines and also
clearly depend on the incubation time with the dendrimer. For 4 h, EC50 is
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Fig. 19: EC50 values for several cancer cell lines according to the MTT
assay.
Table 5: EC50 values of DAB-Am16 after 4 and 24 h lasting incubation of
5 different cell lines with the dendrimer.
4 hours 24 hours
A2780 109.9µgml−1 (65.1 nm) 2.3 µgml−1 (1.3nm)
A431 184.8 µgml−1 (109.6nm) 9.8 µgml−1 (5.8nm)
H1299 22.5 µgml−1 (13.3nm) 9.7 µgml−1 (5.8nm)
MiaPaCa-2 572.2 µgml−1 (339.2nm) 17.2 µgml−1 (10.2nm)
U87MG 113.8µgml−1 (67.5 nm) 12.2µgml−1 (6.7 nm)
highest for MiaPaCa-2 (572 µg/ml) and lowest for H1299 (22 µg/ml), which
means that upon short-term exposure MiaPaCa-2 is the most resistant and
H1299 the most susceptible cell line among those that have been examined.
For 24 h, again MiaPaCa-2 cells have the highest EC50 value (17 µg/ml),
but this time A2780 cells have the lowest EC50 (2µg/ml).
These results indicate that biological differences between the cell lines
not only affect the overall response to DAB-Am16 treatment, but also
influence the time that is necessary to reach a pronounced effect. However,
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(a) MDAMB231 (b) MiaPaCa-2
Fig. 20: Change of EC50 values over time in MDAMB231 and MiaPaCa-2
cell lines.
all the cell lines that have been tested show a large decrease of the EC50
upon the increase of the incubation time from 4 to 24 h. Concentration-
dependent cell death within the plates used for the MTT assay is confirmed
by light microscopy. This observation raises the question if the decrease of
EC50 with the time is linear and if it will reach 0 as cells treated at any
concentration applied would be dead. This question was investigated by
carrying out the MTT assay at more time points between 4 and 24 h as well
as after longer time periods. The results are shown in Fig. 20. Surprisingly,
after approx. 16–18 h incubation (estimated from an asymptotic curve fit),
the EC50 does not further decrease, indicating that toxicity remains stable
after one period of doubling time of these cell lines (17–18 h each). Before
this time point, the slope of the falling EC50 curve was very steep. Thus,
one can suspect that DAB-Am16 causes profound cytotoxicity during the
first cell division after addition to the cell culture medium, however, it only
has a cytostatic effect on the remaining cells. One possible explanation is
that these cells might stop dividing and change to a metabolically dormant
state that could be a protective mechanism to facilitate cell survival until
the cellular environment becomes more favourable. This issue is discussed
in more detail in section 4.2.1.
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3.4.2 Cellular enzyme leakage upon DAB-Am16 treatment
To measure acute cytotoxicity, the LDH assay was applied to A2780 cells,
the results are shown in Fig. 21 on the following page. Clearly, for 4 and
6 h time points an increase in LDH release and thus in cytotoxicity with the
dendrimer concentration can be seen. The EC50 for 4 h is 250µg/ml and
thus more than twice as high as the one for the MTT assay (110µg/ml).
This is a very interesting observation since both assays measure cytotoxicity,
but use different surrogate parameters. From these results, we can conclude
that changes in cellular metabolism precede cell membrane damage. This
is consistent with the apoptotic mode of cell death that is known to be
linked with glycolysis by the pro-apoptotic molecule BAD (Bcl-2 antagonist
of cell death). Danial et al. (2003) found that BAD and glucokinase
(an essential constituent of the glycolysis pathway) are located together
within a mitochondrial complex. Dephosphorylation of BAD upon glucose
deprivation leads to apoptotic cell death. Due to this interconnection one
can assume that MTT assay reveals early apoptotic changes as well as
metabolic slow-down of surviving cells, while LDH assay detects the final
cellular disintegration at a late stage of apoptosis.
3.4.3 Clonogenic cell survival after withdrawal of DAB-Am16
The results of the MTT assay led to the conclusion that cells that survived
the time period equivalent to the doubling time of the particular cell
line might enter a metabolically dormant state that they can leave upon
dendrimer withdrawal. Thus, colony formation assay (CFA) was applied
to test if surviving cells will recover and grow again after 24 h exposure to
DAB-Am16. The number of colonies that grew out of 250 cells that had
been seeded 5 days earlier is plotted in Fig. 22 on the next page for A431
and A2780 cells. Clearly, DAB-Am16 does have a long-term cytostatic effect
on A2780 as the colony formation capability of surviving cells decreases
significantly in a concentration-dependent manner. For A431 cells, there
is no decrease compared to the untreated control for a concentration of
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Fig. 21: Results of the LDH assay with A2780 cells. Error bars represent
the standard deviation.
Fig. 22: Results of the colony formation assay with A2780 and A431 cells.
50µg/ml and only a statistically insignificant decrease at 100µg/ml. Again,
these results highlight the importance of cell-specific features for the effect
of DAB-Am16. All in all, one can see for both cell lines that cellular colony
formation capacity is not completely abrogated after DAB-Am16 treatment,
but it is decreased in a concentration- and cell line-dependent manner.
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Fig. 23: DAPI entrance into DAB-Am16 treated MiaPaCa-2 cells over
time.
3.4.4 Cell membrane permeabilisation occurs within 25 min after
DAB-Am16 addition to MiaPaCa-2 cells
To further investigate the formation of cell membrane holes as a result
of DAB-Am16 action, the ability of cell entrance of the DNA-binding
fluorescent dye DAPI was determined. This dye cannot cross cell membrane
at low concentrations and is used for live/dead cell distinction (Böck 2001;
Doberstein et al. 1993). The fraction of cells that became DAPI-positive
was measured every 5min for a period of 25min in order to determine the
time point when DAB-Am16 action begins. Fig. 23 illustrates the change
of DAPI permeability of MiaPaCa-2 cells at different time points after
addition of 50µg/ml DAB-Am16. The control cells were incubated with
DAPI alone for the longest time period that was used for DAB-Am16 tests
(25min). 3% of control cells were entered by DAPI after this time. After
10min incubation of cells with DAPI and DAB-Am16 together, 8% of cells
were positive for DAPI, indicating that even after such a short incubation
time DAB-Am16 exerts an effect on a subset of cells. Notably, a very steep
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increase in DAPI permeability occurred between 20 and 25min incubation
time (from 11% to 31%). This seems to be the time needed for DAB-Am16
to gain entrance into the cell.
3.5 Changes in cell cycle progression caused by
DAB-Am16
Dendrimers easily bind and condense nucleic acids, as well as enter the
cell and deliver the nucleic acids (e.g. DNA) to the cell nucleus (Dufes
et al. 2005). Consequently, as to the action of the dendrimer inside the
cell, it is reasonable to assume that the dendrimer would enter the nucleus
and interact with the cellular DNA. If this was the case, a disturbance
of the cell cycle could be assumed. To test this assumption, cellular
DNA was quantitatively stained with the intercalating fluorescent dye
PI. Representative results are shown in Fig. 24 on page 84. The relative
percentage of cells in all three cell cycle phases (from left to right G1/G0,
S and G2/M) are shown in this figure. It is obvious that DAB-Am16
causes a massive disturbance of the cell cycle when applied to cells in
vitro. In particular, the fraction of cells that are in the S phase increases
with increasing concentration of the dendrimer. This means that DNA
replication is halted or slowed down in the dendrimer treated cells. Possible
reasons are stalled replication forks due to DAB-Am16 interaction with
nuclear DNA, halted replication after dendrimer-induced DNA damage or
as a consequence of the activation of intracellular molecular stress pathways
that were triggered by the dendrimer but are not due to direct interaction of
DAB-Am16 with the DNA. To test for the possibilities of stalled replication
forks or DNA strand breaks, the presence of phosphorylated histone H2A.X
(γ-H2A.X) within the cell was investigated. A fluorescently coupled antibody
against γ-H2A.X was used for detection, and the fluorescence again was
measured with a flow cytometer. Etoposide was used as positive control
because this compound acts as a topoisomerase II inhibitor which eventually
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leads to DNA strand breaks. Surprisingly, as can be seen in Fig. 25 on
page 85, γ-H2A.X could not be detected in DAB-Am16 treated cells.
Fig. 26 on page 86 shows the change of the cell cycle profile of U87MG
cells upon DAB-Am16 exposure. A clear change is detected even at a
low concentration of 10µg/ml DAB-Am16. It is obvious that DAB-Am16
causes an increase of the amount of cells in the S phase, predominantly
within the beginning of the S phase, at the expense of the G1 phase.
In contrast to U87MG cells, an effect on the cell cycle profile of H1299
cells was only seen at high concentrations of the dendrimer (Fig. 26). At
100 µg/ml DAB-Am16, the change of the cell cycle profile is similar to that
of U87MG cells. However, at 150 µg/ml DAB-Am16, the profile is shifted to
the left, indicating a loss of DNA which is a clear sign of apoptotic processes.
Thus, the effect of the dendrimer on H1299 cells is concentration-dependent
- while at lower concentrations, it causes cell cycle arrest, with increasing
concentration it leads to apoptosis.
To investigate the effect of DAB-Am16 on the cell cycle in more depth,
bromodeoxyuridine (BrdU) was used along with DAPI, a DNA dye that
similar to PI is applied for quantification of cellular DNA. When BrdU
is present in the cell culture medium, cells incorporate it into their DNA
during DNA replication in the S-phase. Cells that incorporated BrdU can
then be detected with immunostaining, while simultaneously the overall
cellular DNA can be quantified with PI or similar DNA dyes. This method
can be applied for two different purposes:
1. Cells that are in the S-phase just before addition of DAB-Am16
can be marked by BrdU incorporation. For this purpose, cells are
pulsed with BrdU for a short time (30min), and DAB-Am16 is added
immediately after BrdU withdrawal for the desired period of time (e.g.
24 h). After DAB-Am16-treatment, cells are immediately harvested,
fixed and stained for BrdU and for DNA quantification. In this way,
cells that were in the S-phase at the moment of DAB-Am16 addition
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Fig. 24: Representative cell cycle profiles of three tumour cell lines. Cells
were treated with different concentrations of DAB-Am16 for 24 h, harvested,
stained with propidium iodide and analysed by flow cytometry. The upper
row shows the untreated controls. The concentrations of DAB-Am16 used
for the treatment of three cell lines, the profiles for which are depicted in the
second and third rows are 50 µg/ml and 100 µg/ml (MDAMB231), 65 µg/ml
and 80µg/ml (A431) and 25 µg/ml and 50µg/ml (A2780), respectively.
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Fig. 25: Immunostaining of A2780 cells for γ-H2A.X upon DAB-Am16
treatment. Etoposide-treated cells are used as positive control. Cells were
treated with either 30 µg/ml or 50µg/ml DAB-Am16 for 3 h, stained and
analysed with a flow cytometer. For easier comparison, the histograms of
the positive control and the dendrimer treated samples have been overlayed
with the histogram of the untreated control (orange).
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(a) U87MG (b) H1299
Fig. 26: Representative cell cycle profiles of the U87MG and H1299 cell line.
The cells were treated, stained and measured as described in Fig. 24. This
figure shows the cell cycle profile of U87MG cells treated with 10 µg/ml (up-
per histogram) and 20 µg/ml (bottom histogram), and H1299 cells treated
with 100 µg/ml (upper histogram) and 150µg/ml (bottom histogram), o-
verlayed with the cell cycle profile of the untreated control cells (light
orange) and normalised by area in order to exclude the influence of different
numbers of measured events.
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can be followed up regarding their cell cycle phase after DAB-Am16
treatment.
2. DAB-Am16 can be applied to the cells as usual, but after completion
of the treatment cells are pulsed with BrdU. Immediately after this
pulse, cells are harvested, fixed and stained as described above. This
method allows the identification of the DNA synthesizing cells after
DAB-Am16 treatment.
Fig. 27 on the following page shows the results of the analysis of cells
pulsed before DAB-Am16 addition. In the untreated control sample, 88%
of all the cells have arisen from those that were in the S phase 24 h earlier
as indicated by their positive BrdU staining. These BrdU-tagged cells
can be found in any cell cycle phase, as can be seen from their DNA
content (represented by DAPI fluorescence on the x-axis). When cells are
treated with hydroxyurea, they accumulate at the beginning of the S phase
as hydroxyurea arrests DNA replication by inhibiting the class I form of
ribonucleotide reductase and thus depleting cellular deoxyribonucleoside
triphosphates (dNTP) pool to the basal level (Bianchi et al. 1986; Hendricks
et al. 1998; Koç et al. 2004). DAB-Am16 treatment does not force the
S-phase cells to stop within the cell cycle, as similar to the control BrdU-
tagged cells can be found in any cell cycle phase. However, the overall
percentage of BrdU-tagged cells compared to non-tagged cells is smaller
than in the control sample (66% for 50µg/ml DAB-Am16). Moreover,
this percentage shows a decreasing tendency with increasing dendrimer
concentration.
When cells are pulsed with BrdU immediately before being collected and
stained, the fraction of BrdU-positive cells corresponds to those cells that
are replicating DNA at that moment (primarily S-phase cells, but minor
incorporation of BrdU can also occur during DNA repair). Fig. 28 shows
that in the control population, approx. 45% replicate their DNA at a given
time point, while for the population treated with 50µg/ml DAB-Am16
the fraction of DNA replicating cells makes up only 22%. The drop in
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Fig. 27: MiaPaCa-2 cells pulsed with BrdU for 30min before addition of
DAB-Am16 for 24 h were harvested immediately after DAB-Am16 with-
drawal, fixed and stained with anti-BrdU-antibody and with DAPI. The
results are shown as a density plot. The amount of DAPI fluorescence
corresponds to the DNA amount inside of the cell as is depicted on the
x-axis. The fluorescence of the BrdU-detection is shown on the y-axis. The
events shown only correspond to single cells, as cell doublets have been
gated out before. The red gate shown on the plots corresponds to BrdU-
positive cells. From upper left to bottom right corner: untreated control,
positive control (hydroxyurea), 5µg/ml, 15µg/ml, 50 µg/ml DAB-Am16
and statistical comparison of the effect of 50µg/ml DAB-Am16 with the
control.
the number of DNA replicating cells depends on the concentration of the
dendrimer, as an intermediate concentration results in an intermediate BrdU-
positive cell number (34% for 15 µg/ml), while the lowest tested DAB-Am16
concentration (5 µg/ml) seems not to have any effect on the proliferation
rate of the cells. Additionally to the decrease of the fraction of BrdU-
positive cells in samples treated with 15 µg/ml and 50 µg/ml DAB-Am16,
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Fig. 28: MiaPaCa-2 cells pulsed with BrdU for 30min after a 24 h treatment
with DAB-Am16 were harvested immediately after BrdU withdrawal. The
staining procedure, the method of illustration and the treatment conditions
are the same as those described for Fig. 27.
there is a slight drop of fluorescence on the BrdU-channel even for cells
that have been categorised as BrdU-negative in the control sample.
Considering the severe decrease of the DNA replication rate seen in
Fig. 28 caused by DAB-Am16 treatment, the drop of the fraction of BrdU-
positive cells in the DAB-Am16 treated samples in Fig. 27 can be explained
by a decrease in cell proliferation, so that BrdU-tagged cells produce less
daughter cells than untreated cells within the same time frame. However,
the important conclusion to be drawn from these experiments is that cell
cycle progression is not completely abrogated by DAB-Am16 but rather
slowed down severely.
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3.5.1 Cyclin D1 levels in A2780 cells change upon DAB-Am16
treatment in a concentration-dependent manner
A2780 cells were treated with different concentrations of DAB-Am16 for
24 h, fixed and stained with an antibody against cyclin D1 as well as with
PI. The results are illustrated in Fig. 29 on the next page. Notably, the
control cells do not show the expected pattern of cyclin D1 upregulation in
G1 and G2, and downregulation during the S phase. M. Huang et al. (2000)
found that A2780 cells have a low expression of cyclin D1, so that one can
assume that under normal conditions, only a background level is detectable
that remains stable in all cell cycle phases. However, upon exposure of
A2780 cells to 10 µg/ml DAB-Am16, a clear upregulation of the cyclin D1
level is observed (Fig. 29) along with an accumulation of the cells at the
beginning of the S phase. With elevated DAB-Am16 concentrations, a
second population appears that has a lower cyclin D1 expression level than
the control cells. These cells with a decreased cyclin D1 level are found
across all the cell cycle levels, while those cells that remain with a high
cyclin D1 level are localised within the beginning of the S phase.
3.5.2 Mitotic index and DNA synthesis are severely decreased after
48 h exposure to DAB-Am16
To test how DAB-Am16 affects the entrance into mitosis, U87MG and
MDAMB231 cells were exposed to different concentrations of the dendrimer
for 24 and 48 h. DNA-synthesizing cells were labelled by EdU incorpor-
ation. Cells were harvested, fixed and stained with an antibody against
phosphorylated histone H3 as well as with a Click-reaction between EdU
and Alexa-Fluor 647. Additionally, DNA was stained with PI. The results
show that the effect of DAB-Am16 on the cell cycle is time- as well as
concentration-dependent (Fig. 30 and Fig. 31). The change in the cell
cycle profile was much more pronounced after 48 h than after 24 h and was
more pronounced at higher dendrimer concentrations. The population of
mitotic cells was virtually depleted after 48 h and the fraction of DNA-
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Fig. 29: A2780 cells treated with different concentrations of DAB-Am16
were stained for the level of cyclin D1. The y-axis shows the relative
fluorescence on a hyperlogarithmic scale while the x-axis represents the
DNA amount of the cells detected by PI staining.
synthesizing cells decreased dramatically. Strikingly, the number of cells
with hyperdiploid PI signal increased strongly. This contravenes the drop
of DNA synthesis, thus posing the question how cells with hyperploid DNA
content can arise without synthesis of new DNA. A possible explanation of
these observations is that the number of hyperploid cells does not increase,
but instead propidium iodide intercalation with the DNA is promoted by
changes of DNA conformation. This effect has been observed by other
groups (Ferlini, Biselli et al. 1996; Ferlini, Di Cesare et al. 1996; Prosperi
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Fig. 30: U87MG cells were incubated with DAB-Am16 either at 10 or
at 60 µg/ml for 48 h. Control cells were grown without DAB-Am16. Sub-
sequently, the cells were incubated with the uridine analogue EdU which
is incorporated into newly synthesised DNA similarly to BrdU. EdU was
then fluorescently labelled to measure the fraction of DNA synthesizing
cells. EdU fluorescence is shown on the y-axis of plots in the right column.
To simultaneously identify mitotic cells, mitosis-specific phosphorylation
of histone H3 was detected (y-axis of plots in the left column). Finally,
cellular DNA was stained with PI which is shown on the x-axis on all plots.
et al. 1991) and also applies to several other DNA dyes (ethidium bromide,
Hoechst33258), but is absent in cells stained with mithramycin or 7-AAD.
This might be due to different sizes of these dyes (7-AAD: MW1270; mithra-
mycin: MW1085; PI: MW668) or different binding/intercalation properties.
In fact, Prosperi et al. showed that PI fluorescence intensity increases upon
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Fig. 31: Data from Fig. 30 as a histogram for better overview. Note the
break within the y-axis due to large differences in the number of DNA
synthesizing and mitotic cells.
partial digestion of DNA with conformation-specific endonucleases that
preferentially cleave supercoiled active chromatin, but PI fluorescence does
not increase after digestion of the DNA with sequence-specific nucleases.
Ferlini, Di Cesare et al. found the pseudo-hyperploid population to be early
apoptotic cells that share light scatter properties with cells within the sub-
G1 peak and exhibit the uptake of the non-permeant DNA dye ethidium
bromide before fixation. Another possible explanation is that DAB-Am16
itself interacts with the DNA and causes a conformational change, thus
allowing more PI molecules to intercalate with the same amount of DNA.
3.6 DAB-Am16 triggers apoptotic cell death
Five characteristics that change during apoptosis were recorded for each cell:
light scattering, mitochondrial membrane potential, cell membrane integrity,
caspase activation and DNA fragmentation. Fig. 32a on the following page
shows a schematic overview on the expected change in light scattering
properties of apoptotic cells, while Fig. 32b shows a scheme of the 2D plot
of mitochondrial membrane potential and cell membrane permeability.
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3.6.1 Apoptosis in MiaPaCa-2 cells
To identify the order of cell death events due to DAB-Am16 exposure, gates
were created around all distinguishable cell populations. The gates are
explained in Fig. 33 on the next page and Fig. 34 on page 96.
It is possible to select a particular cell population on one plot with a
gate, and highlight the selected cells within another plot. For example, one
can draw a gate around the “healthy” cell population on the light scatter
(LSC) cytogram and highlight all those cells that fall into this gate with
the violet colour within the DAPI vs. TMRE dot plot. In this way, one
gets the information about the TMRE and DAPI status of those cells that
appear healthy on the LSC cytogram. The results are illustrated in Fig. 35
on page 96. On the right, the gating of distinct populations on the LSC
plot is shown again. On the TMRE vs. DAPI plot, those cells that are
within the P8 gate are highlighted violet. Clearly, the vast majority of these
cells are TMRE-positive and DAPI-negative, thus showing all the features
we would expect from healthy cells. While the untreated control sample
(a) Light scatter properties of apoptotic
cells
(b) Mitochondrial potential and cell
membrane integrity assay
Fig. 32: Schematic representation of the measurement of apoptotic charac-
teristics of cells.
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Fig. 33: The gate setting strategy for investigation of apoptosis with
flow cytometry. MiaPaCa-2 cells were stained with TMRE, DAPI and
PhiPhiLux. The upper row shows two representations of the control sample:
Forward scatter (FSC) vs. Side scatter (SSC) on the left, and TMRE vs.
DAPI on the right. The same two representations are applied on the sample
treated with 125 µg/ml DAB-Am16 for 2 h which is shown in the bottom
row. Four populations are distinguishable on the FSC vs. SSC plot: P8
(violet gate, “healthy cells” in Fig. 32a), P6 (darkcyan gate, part of the
“healthy cells” in Fig. 32a), “dying” (pink gate, “apoptotic cells” in Fig. 32a)
and P7 (lightgreen, “late apoptotic” in Fig. 32a). Debris as depicted in
Fig. 32a is not shown in this figure. The TMRE vs. DAPI plot is divided
into quadrants that are called LL4 (lower left, darkgreen), UL4 (upper
left, violet), UR4 (upper right, red) and LR4 (lower right, brown). The
percentages stated in each gate refer to the fraction of cells located within
this gate out of the whole population that has been measured. Furthermore,
caspase-3 positive cells are gated orange as shown on the histogram in
Fig. 34.
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Fig. 34: Caspase-3 activation in MiaPaCa-2 cells. The x-axis shows the
relative fluorescence of the cleaved caspase-3 substrate, while the y-axis
corresponds to the number of cells. The orange gate quantifies the number
of caspase-positive cells.
Fig. 35: Location of
cells from the P8 gate
(with normal light scat-
tering) on the the LSC
and the TMRE vs.
DAPI plots. The gate
was set on the LSC
plot and the cells within
the gate were then dis-
played on the TMRE vs.
DAPI plot with the vi-
olet colour. The upper
row shows the untreated
control sample and the
lower row shows Mia-
PaCa-2 cells after expo-
sure to 125µg/ml DAB-
Am16 for 2 h.
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contains 69.64% of cells in the P8 gate on the LSC plot, only 35.46% of
cells treated with 125µg/ml DAB-Am16 are within this gate, thus showing
the drop in cell viability upon dendrimer treatment.
Once cells enter the apoptotic pathway, their side scatter usually increases
and caspase-3 becomes activated. Cells with increased side scatter properties
are gated with the P6 gate in Fig. 36a on the following page on the light
scatter plots (left column). To check for the TMRE and DAPI status of these
cells, we again apply the same strategy as described above, highlighting
only those cells that were within the P6 gate on the TMRE vs. DAPI dot
plot with the darkcyan colour (right column in Fig. 36a). In the untreated
sample (upper row left), 6% are found within the P6 gate, while this
value rises to 14% in the DAB-Am16 treated population (bottom row left).
When visualised on the TMRE vs. DAPI plot, the vast majority (93%) of
these cells in the control sample are within the lower right corner (LR4),
thus having an intact mitochondrial membrane potential and an intact cell
membrane. Only 6% are within the upper right quadrant (UR4). However,
the situation is different for the dendrimer treated sample. A substantial
number of P6-cells (33%) is found to be DAPI- and TMRE-positive. The
statistical data for the distribution of treated and untreated P6-cells between
the quadrants is shown in Fig. 36b. These results indicate that the first
step on the way to cell death upon DAB-Am16 treatment is hole formation
within the plasma membrane as well as an increase of the side scatter of
light.
Having analysed the first signs of apoptotic changes within the cells
upon DAB-Am16 treatment, the question arises at which point caspase-3
is activated within the cells as this is often considered to be the point-of-
no-return for the apoptotic process (Green 2000; Hengartner 2000; Kumar
1998). Moreover, as the reports on the order of caspase-3 activation and
mitochondrial membrane potential drop are controversial, the order of
these events in the case of DAB-Am16 treated MiaPaCa-2 cells is to be
investigated. The location of caspase-positive cells on the LSC and the
TMRE vs. DAPI plots is shown in Fig. 37a on page 99 and the statistical
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(a) Location of cells from gate P6 within
the TMRE vs. DAPI plot
(b) Distribution of MiaPaCa-2 cells
with increased side scatter within the
TMRE/DAPI plot
Fig. 36: Location and distribution of MiaPaCa-2 cells with increased side
scatter properties within untreated and dendrimer treated samples on the
TMRE vs. DAPI plot. The stars indicate a significant (p< 0.05) difference
between the untreated and the dendrimer-treated sample.
distribution of caspase-positive cells within the TMRE vs. DAPI plot is
depicted in Fig. 37b. Clearly, the vast majority of caspase-positive cells
within the dendrimer-treated sample is located either within the P6 gate
(cells with elevated right angle light scatter) or within the “dying” cell
population (cells with decreased forward light scatter), thus confirming
the association of these light scatter properties with the commitment to
apoptotic cell death. Within the TMRE vs. DAPI plot, far most of the
caspase-positive cells are found within the lower right quadrant in the
untreated sample, but this changes upon dendrimer treatment. In the
treated sample, there is a significant decrease of the fraction of caspase-
positive cells within the LR quadrant and a significant increase within the
UL quadrant as well as an insignificate increase within the UR quadrant.
However, almost no cells are found within the LL quadrant. This indicates
that concurrent with caspase activation, the cells first acquire holes in the
cell membrane (translocate from LR to UR on the plot in Fig. 37a) and then
quickly lose the mitochondrial potential (translocation from UR to UL).
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(a) Activation of caspase during
MiaPaCa-2 apoptosis.
(b) Distribution of MiaPaCa-2 cells with
activated caspase-3 within the TMRE/
DAPI plot
Fig. 37: Location and distribution of MiaPaCa-2 cells with activated
caspase-3 (marked with the orange colour) within untreated and dendrimer
treated samples on the TMRE vs. DAPI plot. The stars indicate a significant
(p< 0.05) difference between the untreated and the dendrimer-treated
sample.
However, caspase-positive cells are not found within the cell population
that proceeded to the very last stage of cell death (LL quadrant).
Next, the mitochondrial and cell membrane status of cells designated
as “dying” (having decreased forward light scatter values) within the LSC
plot is to be analysed using the same strategy as above. Again, cells that
are gated as “dying” on the LSC plot are highlighted within the TMRE
vs. DAPI dot plot as pink dots and the fraction of these cells within the
four quadrants is determined. As can be seen from Fig. 38, the number of
these cells is again much lower within the control sample (17.11%) than
within the dendrimer-treated cell sample (43.49%). Their distribution
differs significantly as well. While most of these cells are within the lower
right quadrant in the control population, the vast majority is within the
upper left quadrant in the treated cell population, i.e., these are mostly
cells with a permeabilised plasma membrane and collapsed mitochondrial
membrane potential which previously was determined to be the ultimate
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(a) Location of cells from gate “dying”
within the TMRE vs. DAPI plot
(b) Distribution of MiaPaCa-2 cells with
decreased forward scatter within the
TMRE/DAPI plot
Fig. 38: Location and distribution of MiaPaCa-2 cells with decreased
forward light scatter properties within untreated and dendrimer treated
samples on the TMRE vs. DAPI plot. The stars indicate a significant
(p< 0.05) difference between the untreated and the dendrimer-treated
sample.
state for caspase-positive cells. Thus, so far, the way to death of MiaPaCa-2
cells upon DAB-Am16 treatment was seen to lead through cell membrane
permeabilisation, caspase-3 activation, increase of right angle light scatter,
then decrease of both side and forward light scatter and collapse of ∆Ψm.
The very last stage of apoptosis is characterised by cellular disintegration,
which comes along with a large drop of light scattering, loss of DNA and
finally only debris remains of the cell. In Fig. 39 on the following page,
this is illustrated by setting gate P7 around cells that have extremely low
light scattering properties and highlighting these cells with a green colour
within the TMRE vs. DAPI plot. Evidently, these cells are located in the
lower left quadrant, thus finally having lost DAPI fluorescence due to loss
of DNA as DAPI is a DNA-binding dye, and also possessing a collapsed
mitochondrial membrane potential.
In summary, the order of the events on the way to cell death after
DAB-Am16 exposure is as follows:
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(a) Location of cells from gate P7 within
the TMRE vs. DAPI plot
(b) Distribution of MiaPaCa-2 cells with
severely decreased light scatter within
the TMRE/DAPI plot
Fig. 39: Location and distribution of MiaPaCa-2 cells with severely de-
creased forward and right angle light scatter properties within untreated
and dendrimer treated samples on the TMRE vs. DAPI plot. There is
no significant difference between the untreated and the dendrimer-treated
sample in any of the quadrants.
Fig. 40: Summary of the death path of MiaPaCa-2 cells upon DAB-Am16
treatment as represented by multicolour flow cytometry measurements.
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1. Cell membrane permeabilisation, increase of right angle light scatter
(side scatter) and caspase-3 activation
2. Loss of mitochondrial membrane potential, decrease of forward light
scatter and finally loss of caspase-3 activity
3. Further decrease of both forward and side light scatter, loss of DAPI
fluorescence, cellular disintegration
A graphical representation of the order of the events is shown in Fig. 40 on
the previous page.
Considering the discussion in section 3.4.2 that according to the MTT and
LDH assays metabolic changes precede leakage of large cytosolic enzymes
out of the cell, the results of the TMRE/DAPI staining first seem to
contradict those findings because here cell membrane permeabilisation is
detected by DAPI influx prior to metabolic changes by collapse of ∆Ψm. A
plausible explanation is that DAB-Am16 first enters the cell via formation
of cell membrane holes in the nanosize range, then exerts its cytotoxic effect
and only at the last stage large holes in the cell membrane occur as a late
apoptotic event. When DAB-Am16 (MW 1,687) forms nanoholes in the
cell membrane, DAPI (MW 350) can enter the cell through these holes,
while LDH (MW 140,000) is too big to leave the cell through these holes
and is only released upon final cell membrane disintegration.
3.6.2 Apoptosis in A2780 cells
Fig. 41 on the following page shows the distribution of A2780 cells between
the quadrants on the TMRE vs. DAPI plot after treatment with 70 µg/ml
DAB-Am16 for 4 h compared to the untreated control. In the control
sample, almost all cells are located within the LR quadrant, i.e. they have a
normal mitochondrial membrane potential and an intact cell membrane. In
contrast, less than 50% of dendrimer-treated cells are located within this
quadrant. Most of the remaining cells in this sample are found within the
UL quadrant, indicating a collapsed mitochondrial membrane potential and
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Fig. 41: Distribution of untreated and DAB-Am16 treated A2780 cells on
the TMRE vs. DAPI plot. The treated population was exposed to 70 µg/ml
DAB-Am16 for 4 h. The stars indicate a significant (p< 0.05) difference
between the untreated and the dendrimer-treated sample.
Fig. 42: Distribution of caspase-positive A2780 cells on the TMRE vs.
DAPI plot. The treated population was exposed to 70 µg/ml DAB-Am16
for 4 h. The stars indicate a significant (p<0.05) difference between the
untreated and the dendrimer-treated sample.
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Fig. 43: Distribution of A2780 cells with decreased forward light scatter on
the TMRE vs. DAPI plot. The treated population was exposed to 70 µg/ml
DAB-Am16 for 4 h. The stars indicate a significant (p< 0.05) difference
between the untreated and the dendrimer-treated sample.
a perforated plasma membrane. Moreover, 38% of the dendrimer-treated
cells were found to be caspase-positive (control sample: 6%) and 35%
exhibit a decreased forward light scatter (control sample: 2%). Thus,
DAB-Am16 shows a clear cytotoxic effect on A2780 cells within a short
time frame, triggering the apoptotic pathway.
The distribution of caspase-positive cells on the TMRE vs. DAPI plot
is shown in Fig. 42 on the previous page. 60% of caspase-positive cells
in the control sample are within the LR quadrant, and almost all the
other cells are found within the UR quadrant. Thus, the vast majority of
caspase-positive cells within the control sample have an intact mitochondrial
membrane potential, while some of them have a perforated cell membrane,
presumably due to the mechanical stress caused by cell sample handling
before the measurement. In contrast, 75% of caspase-positive cells within
the dendrimer-treated sample are in a much more advanced stage on the
way to cell death, being located in the UL quadrant and thus having
both, a collapsed ∆Ψm and holes in the cell membrane. Significantly
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Fig. 44: The fraction of cells within particular gates is plotted against
duration of exposure to 50µg/ml DAB-Am16. The stars indicate a signific-
ant (p< 0.05) difference between the untreated and the dendrimer-treated
sample.
less caspase-positive cells are located in LR and UR quadrants within the
dendrimer-treated sample.
A similar difference in distribution is also seen for the population of cells
that show a decreased forward scatter (“dying” cells on the LSC plot) as
can be seen in Fig. 43 on the preceding page. More than 80% of dendrimer-
treated cells from this population are found within the UL quadrant as
it is the case for 75% of caspase-positive cells. In contrast to the control,
almost none of the “dying” cells are located within the LR quadrant.
3.6.3 Apoptosis in U87MG cells
U87MG cells were used to characterise how the number of cells with apop-
totic features changes with increasing duration of exposure to DAB-Am16.
TMRE and DAPI fluorescence as well as the light scattering properties of
cells were measured after exposure to the dendrimer for 30, 60, 90, 120
and 150min and compared to the untreated control sample. The results
105
3 Results
are shown in Fig. 44 on the previous page. Already after 30min a signific-
ant drop of the number of cells within the LR quadrant and a significant
increase of cells within the UL quadrant is observed. An increase of the
“dying” cell population (according to the LSC plot) is also seen after 30min,
although this difference is not statistically significant. During the next time
points up to 120min, the percentages of cells within the designated gates
do not change. However, after 150min, all the gates show a significant
difference compared to the control: the LR-quadrant population clearly
decreases, while the percentage of cells within the other three quadrants
and the percentage of cells with decreased forward light scatter (“dying”)
increases significantly. These results indicate that the cytotoxic effect of
DAB-Am16 is observable already after 30min. However, within the next
1.5 h (time point 120min), there is no further change. Between 120 and
150min, another clear change takes place, leading to a further rise of cells
exhibiting apoptotic properties.
3.7 Cellular RNA content decreases upon DAB-Am16
exposure
Acridine Orange (AO) is a metachromatic dye that fluoresces in different
wavelengths dependent on if it is bound to single-stranded or double-
stranded nucleic acids. After selective denaturation of RNA it is possible to
stain DNA and RNA with green and red colour, respectively. This allows
to measure RNA content of cells and correlate it to their cell cycle phase.
Fig. 45 on page 108 shows the results of AO staining of U87MG cells.
To exclude doublets, the area of the green fluorescence signal was plotted
against its height and only the cells on the diagonal were selected as singlets.
According to Fig. 45, less than 1% of singlets are RNAlow, while RNAlow
cells constitute 14% of the treated cell population. The percentage of cells
within the G2 phase is approximately the same in both samples (35% in
control and 37% in treated sample), but while 76% of G2 cells (27% out
of 35% of overall singlets) are found in the upper right quadrant within
106
3 Results
the control cell population, only 31% of G2 cells in the dendrimer-treated
sample are in this quadrant, indicating a significantly lower percentage
of cells with a high RNA content. When the RNAlow cell population is
overlayed with the whole cell population on the DNA histogram plot (upper
panel in Fig. 45), a peak arises within the S-phase cells after DAB-Am16
treament, while most of RNAlow control cells are located within the G1
and G2 phases. Quantitatively, 33% of the RNAlow cells of treated sample
are located in the S-phase, while only 19% of the RNAlow control sample
cells are within the S-phase. Accordingly, less of RNAlow cells are in G1
and G2 phases in the treated sample (13% and 20%, respectively) than in
the control (34% and 27%, respectively). Another difference is the high
number of RNAlow cells within the cell population with a DNA content
higher than that of G2 (possible hyperploid cells) in the treated cell sample.
Thus, DAB-Am16 leads to a markedly decreased RNA content of cells,
especially in the S-phase and the hyperploid cell populations.
Fig. 46 on page 109 shows the results of the AO staining for A431 cells
either untreated or treated with 75µg/ml DAB-Am16 for 24 h. A similar
pattern is observed as for U87MG cells:
• There is a higher fraction of RNAlow cells within the dendrimer-treated
sample than within the control (5.18% vs. 0.87%).
• In the control population, 68.6% of G2 cells have a high RNA content
compared to 20% in the dendrimer-treated sample.
• More RNAlow cells are located within the S-phase in the treated
sample compared to the control (41.49% vs. 26.49%), while less cells
are found in G1 (26.00% vs. 35.10%) and approx. the same number
is found in G2 (13% vs. 9.93%).
The only difference is the lack of RNAlow cells within the hyperploid cells
that, however, make up only a small fraction of the overall cell population.
MiaPaCa-2 cells show a markedly different cell cycle change after treat-
ment with DAB-Am16 compared to other cell lines. They do not show
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Fig. 45: Differential staining of DNA and RNA of U87MG cells: (a) non-
treated control and (b) treated with 10µg/ml DAB-Am16 for 24 h. Singlets
have been selected by plotting Area vs. Height of the DNA staining colour
(not shown). The bottom row shows a density plot of all singlets with green
(DNA) fluorescence on the x-axis and red (RNA) fluorescence on the y-axis.
Those cells that exhibit a particularly low RNA content are selected with a
violet gate. The upper panel shows DNA histograms (red) and an overlay
of the RNAlow cells (violet). The histograms are normalised to the area
and are smoothed due to the very low number of RNAlow cells.
S-phase arrest, but exhibit G2-phase arrest instead. This poses the question
how they behave in terms of the distribution of RNAlow cells compared
to A431 and U87MG cell lines. Fig. 47 illustrates that again there is a
higher percentage of RNAlow cells within the DAB-Am16 treated cell sample
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Fig. 46: Differential staining of DNA and RNA of A431 cells: (a) non-
treated control and (b) treated with 75µg/ml DAB-Am16 for 24 h. Analysis
was performed in the same way as described for Fig. 45.
compared with the control (16% vs. 3%), but unlike the other cell lines,
the more RNAlow MiaPaCa-2 cells in the treated sample accumulate in the
G2 phase of the cell cycle than within the control sample (13% vs. 5%).
Fig. 48 on page 111 shows a plot of the fraction of RNAlow cells dependent
on the DAB-Am16 concentration applied for all three cell lines that have
been discussed above. For all three cell lines, there was an increase of the
percentage of RNAlow cells with rising DAB-Am16 concentration. However,
while for MiaPaCa-2 cells, this percentage rose only up to approx. 10 µg/ml
and then remained stable at about 14%, the increase for A431 cells was
109
3 Results
Fig. 47: Differential staining of DNA and RNA of MiaPaCa-2 cells: (a)
non-treated control and (b) treated with 50µg/ml DAB-Am16 for 24 h.
Analysis was performed in the same way as described for Fig. 45.
linear over the whole range tested, but the values were lower (up to approx.
5% at 75 µg/ml). For U87MG, the initial increase was similarly steep as for
MiaPaCa-2, but no data is available for DAB-Am16 concentrations higher
than 10 µg/ml.
3.8 Effect on tumour cells in vivo
The tumour size and the animal weight were first measured on day 7 after
tumour implantation. On day 8 since the first measurement, the animals
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Fig. 48: Fraction of cells with a low RNA content within samples of
MiaPaCa-2, A431 and U87MG cells dependent on the concentration of
DAB-Am16 that the cells had been exposed to.
with growing tumours (17 out of 20 injected) were assigned to one of
the three groups “control” (6 animals), “DAB-Am16-treated” (6 animals)
and “gemcitabine” (5 animals) so that each of the groups contained a
representative set of tumour growth kinetics and tumour sizes. The first
injection of DAB-Am16 was carried out on the same day, while gemcitabine
was injected one day later for the first time. Tumour size and animal weight
were recorded three times a week. For data analysis, the tumour size of
each animal on each day of measurement was normalised to the tumour
size of this animal of the first day of measurement. The mean relative
tumour growth for each group was plotted with error bars representing the
standard error. Animals were culled on the day of the fourth consecutive
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Fig. 49: The relative tumour size over time. The x-axis shows the number
of days since the first size measurement (8 days after xenograft injection).
Measurements were performed on each day of the injection of DAB-Am16
since treatment onset and on day 25 before culling the animals.
measurement at which the mean tumour size of the DAB-Am16-treated
group was significantly (p<0.05) smaller than the mean tumour size of the
control group. One animal of the DAB-Am16-treated group was found to
be dead without any obvious reason on the next day after the 7th injection.
Fig. 49 shows that the control tumours grew fivefold within 25 days with a
clear tendency to further growth, while the tumours within the DAB-Am16-
treated group had on average approx. twofold larger volume than at the
beginning, remaining stable in size since the 2nd injection of DAB-Am16.
There was no significant difference between DAB-Am16 and gemcitabine
treatment with respect to tumour size. Fig. 50 on the following page shows
that the weight of all animals dropped transiently after the first DAB-Am16
injection, but the animals recovered quickly and the weight remained stable
after the second injection. This is in accordance with previous observations
by Dufes et al. (private communication).
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Fig. 50: The animal weight over time. Animals were weighed on the same
days as tumour measurements (Fig. 49) and additionally on day 11 due to
the severe weight drop detected on day 10.
As tumour growth was inhibited by DAB-Am16, one would assume that
the proliferation capacity of the tumour cells was compromised. To test this
hypothesis, immunohistochemical analysis of Ki-67 expression of tumour
tissue was performed. Ki-67 is a proliferation marker that is expressed
by proliferating cells during all cell cycle phases, but is not expressed in
resting G0 cells (Scholzen et al. 2000). For each individual tumour, three
pictures were made on random positions within the tissue sample, and all
three pictures were used for visual assessment of Ki-67 expression for each
tumour. An example of the grading of one tumour per rating value is shown
in Fig. 51 on the next page. An overview of the absolute frequency and
cumulative relative frequency of the rating values for each treatment group
is shown in Table 6 on page 115. Unfortunately, due to the small amount
of available tissue especially in the treated groups, not all tumours could
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(a) Score 1 (b) Score 1 (c) Score 1
(d) Score 2 (e) Score 2 (f) Score 2
(g) Score 3 (h) Score 3 (i) Score 3
Fig. 51: Examples for Ki-67 expression rating of the tumour tissue sample
after immunohistochemical staining. For each of the assessed tumours three
pictures on random positions of the slide with a magnification of 40x were
made. The assignment of the score is based on the assessment of all three
pictures for each tumour.
be analysed. Intriguingly, no significant difference in Ki-67 expression can
be inferred from the available data.
To compare cell cycle progress in vitro and in vivo, four tumours of the
control and of the DAB-Am16 group were dissociated into a single-cell
suspension. The cell cycle profiles were then measured by DNA staining
with propidium iodide. Fig. 52 shows the cell cycle profile of the four
control tumours. Clearly, G1 phase is the most prominent phase on the
histogram. Interestingly, all control tumours also have a distinct peak
within the S phase. This is opposite to the cell cycle profile seen in vitro
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Table 6: The degree of Ki-67 expression was assessed for each animal.
The cumulative relative frequency of each rating within each group was
calculated to facilitate comparison between the three treatment groups.
Rating Absolute frequency Cumulative relative frequency
Control DAB-Am16 Gemcitabine Control DAB-Am16 Gemcitabine
1 4 1 1 0.7 0.3 0.2
2 2 1 3 1.0 0.7 1.0
3 0 1 0 1.0 1.0 1.0
Fig. 52: Cell cycle profile of cells derived from tumours of four randomly
selected animals from the control group.
with MiaPaCa-2 cells where the S phase approximates an even plateau
below G1 and G2/M peaks. As for the DAB-Am16-treated tumours, 3 out
of 4 tested cell samples seem to completely lack S phase cells and have
only very small G2/M peaks. It is not known where this striking difference
between control and treated tumours is a result of cell cycle phase-selective
cell death or of a prevention from further cycling of those cells that reached
G1.
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Fig. 53: Cell cycle profile of cells derived from tumours of four randomly
selected animals from the dendrimer treated group.
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4 Discussion and implications
4.1 Analytical characterisation of DAB-Am16
The identity, purity and stability of the DAB-Am16 dendrimer used for
further experiments was confirmed with 1H NMR, 13C NMR and 1H COSY
spectroscopy, ESI and MALDI-TOF mass spectrometry and CHN analysis.
The dendrimer was found to be highly pure with only a minor fraction
of molecules having small defects (absence of one or two 3rd generation
branches) and a small unidentified peak at m/z 663.5 in mass spectra that
is probably also responsible for an additional peak in the NMR spectrum
at approx. 18.5 ppm. The dendrimer did not degrade even after two years
of storage within an opened storage container. Formal short term stability
test of solutions of dendrimer in water demonstrated the material to be
stable for at least 6 days at –20 °C, 4 °C, sroom temperature and at 37 °C.
An important obstacle to the development of new drugs for clinical use
is that many potential drug molecules are prone to decomposition over
time. For safety reasons, it is crucial that the administered drugs remain
stable during long-term storage. The stability issue becomes even more
important in outpatients’ care as patients might store drugs for a longer
time without monitoring the expiry date, and might also store the drugs in
a warm environment that promotes decomposition. A lot of effort is put
into development of stable drug formulations. The stability of DAB-Am16
over time and temperature range makes it a good drug candidate.
4.2 In vitro investigation
4.2.1 Cytotoxicity and drug resistance
The in vitro part of the work described in this thesis confirms that the
dendrimer DAB-Am16 has cytotoxic and cytostatic effects on a wide range
of human cancer cell lines in a time- and concentration-dependent manner.
Although the sensitivity to DAB-Am16 varies between cell lines, for all
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tested cell lines, the EC50 remains within the same concentration range and
drops in an exponential way within the first doubling time. However, longer
exposure to DAB-Am16 up to 96 hours does not further decrease viability,
indicating that a small subset of the overall cell population remains viable
for an extended time frame. Nonetheless, the ability to further divide and
build colonies is reduced for these cells even after withdrawal of DAB-Am16
as has been shown in the colony formation assay, indicating a permanent
damage caused by DAB-Am16 even within the resistant subpopulation.
Thus, within the first doubling time of the cell population DAB-Am16 exerts
a cytotoxic effect on the majority of cells, while with further exposure time
a cytostatic effect is observed for a small number of surviving cells.
As with each surrogate marker, caution should be exercised when conclu-
sions are drawn from assay results. Although the MTT assay is generally
considered to be a viability assay, one must be aware that it measures
enzyme activity of the entire cell population, which of course decreases with
the number of viable cells, but might also be influenced by the metabolic
activity of the cells. A transient effect leading to decreased enzyme activity
within viable cells cannot be ruled out. At long incubation times, cell death
could also be counteracted by division of the few remaining resistant cells.
These two fundamentally different scenarios might both lead to apparently
same assay results. Having said that, the MTT assay is a good way to
assess drug effect at a range of different concentrations at a high throughput
if the experimentator is well aware of the limitations. In the case of the
experiments conducted for this thesis, microscopic observations confirmed
an enormous change of the morphologic appearance of the cells as well
as the dramatic increase of the number of floating (dead) cells at high
DAB-Am16 concentrations.
There must be an intracellular, perhaps a genetic difference between
the highly sensitive and the long-term surviving cell subpopulations. It
is tempting to speculate that the surviving cells might bear stem-cell like
properties. The concept of cancer stem cells (CSCs) being the initiators of
malignant diseases has been first proposed in mid-90’s for acute myeloid
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leukemia (Bonnet et al. 1997; Lapidot et al. 1994). Since then, this concept
has been extended to a number of other malignancies including pancreatic
(Hermann et al. 2007; M. P. Kim et al. 2011; Li et al. 2007), brain (Lathia
et al. 2010; Rasper et al. 2010; S. K. Singh et al. 2003) and breast cancer
(Ginestier et al. 2007; Al-Hajj et al. 2003; Lorico et al. 2011; Wright et al.
2008). The key characteristics of CSCs are tumorigenicity, self-renewal and
multipotency (Lonardo et al. 2010; Tabatabai et al. 2011). Furthermore,
CSCs are particularly resistant to chemotherapy due to overexpression of
drug eﬄux pumps and are supposed to be the cause of relapse after tumour
treatment (Frank et al. 2010; S. Zhou et al. 2001). Expression of members
of the ATP-binding cassette family such as P-glucoprotein (MDR1) and
ABCG2 not only causes eﬄux of cytotoxic drugs, rendering these cells
resistant to conventional chemotherapeutics, but also can lead to eﬄux
of lipophilic fluorescent dyes like the DNA-staining dye Hoechst 33342,
allowing distinction of cells that express drug eﬄux pumps and those that
don’t with flow cytometry. Cells that appear negative for fluorescence of
Hoechst 33342 are called “side population” and are supposed to be cancer
cells (Takubo et al. 2008). In animal experiments, CSCs are considered
to be the tumour-initiating cells (TICs) that are responsible for growth of
xenotransplantats in animal models (Lara-Padilla et al. 2012). Apart from
their definition as side population, CSCs can be distinguished from the
bulk of tumour cells by specific markers, but these markers differ between
tumour types. For example, pancreatic cancer stem cells are characterised
by CD44+CD24+ESA+ marker expression profile (Li et al. 2007) with
metastatic CSCs also being CD133-positive (Hermann et al. 2007), while a
panel of glioblastoma stem cell markers has been suggested including CD133,
integrin α6 and A2B5 expression (Lathia et al. 2010; Ogden et al. 2008;
S. K. Singh et al. 2003). Given the fact that a lot is already known about
the unique characteristics of CSCs for individual cancer types, it would
be interesting to isolate the long-term survivors of in vitro DAB-Am16
treatment and to determine if stem-cell like properties can be detected.
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However, CSCs/TICs are usually found at an extremely low concen-
tration. Ishizawa et al. (2010) systematically compared TIC frequency
in human pancreatic, non-small cell lung, and head and neck carcinomas
identified with different mouse models. In all cases, the frequency did
not exceed 0.04%. In contrast, the survival rate in the MTT experiments
with DAB-Am16 was at about 10%. Thus, another mechanism might be
responsible for the observed long-term resistance. Similarly, it is unlikely
that the resistance occurs in a genetically distinct cell subset that is al-
ways present due to genetic heterogeneity of cancer cells, as this again
would most probably be true for less than 1% of the population. Recently,
Sharma et al. (2010) showed that cancer cells can switch to a metastable
drug-tolerant state upon exposure to high drug concentrations. These
drug-tolerant cells (DTCs) give rise to long-term persisters including those
that resume normal proliferation despite presence of the drug. This is
due to chromatin remodeling associated with insulin-like growth factor 1
(IGF1) receptor signaling and KDM5A histone lysine demethylase activ-
ity resulting in reversible epigenetic modifications. Interestingly, in this
experiment DTCs were shown to express the stem-cell markers CD133
and CD24. However, while DTPs remained quiescent, they gave rise to a
small subset of proliferatively active drug-tolerant cells whose CD133/CD24
expression profile resembled that of the parental drug-sensitive cell popu-
lation. The authors argue that although there seems to be a relationship
between DTCs and CSCs, the nature of this relationship remains to be
clarified. In another study, Yan et al. (2011) aimed to mimic the chronic
drug exposure pattern of metronomic chemotherapy in prostate cancer
cells. Yan et al. also observed the occurrence of a reversible drug-tolerant
state within a distinct cell subset associated with chromatin remodeling.
Strikingly, these DTCs showed a severe downregulation of CD44 that is a
known marker of CSCs in prostate cancer. The CD44 downregulation is
accompanied by a decreased or even abrogated tumour-initiating capacity
and clonogenicity. However, after 3 months incubation of DTCs in drug-free
medium, they almost completely regain the parental tumorigenicity. It
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remains to be clarified if similar reversible DTCs are responsible for the
appearance of a DAB-Am16-tolerant/resistant cell subset. In accordance
with the observations of Yan et al., the DAB-Am16-tolerant cells show
a diminished clonogenic potential. An analysis of the expression of CSC
marker panels for the individual cell lines used for this study would help to
understand the nature of the DAB-Am16-tolerant cell subset.
All in all, two hypotheses arise concerning the tolerant/resistant cell
populations:
i) The persisters are CSCs. These cells often exhibit multidrug resistance
conferred either by eﬄux pumps that efficiently transport drugs out
of the cell, or by their quiescence that renders them elusive to drugs
which predominantly affect cycling cells.
ii) The DAB-Am16-tolerant cells acquire epigenetic modifications that
provide a reversible state of insensitivity to the drug. These are not
necessarily CSCs. Similar to what Yan et al. (2011) suggest for their
studies with paclitaxel and other chemotherapeutics, DAB-Am16
might even preferentially eliminate CSCs as the clonogenicity of the
DTCs is lower than that of the parental cell population.
Clearly, these hypotheses need to be tested in order to better understand
possible resistance mechanisms that could occur upon DAB-Am16-treatment
in clinical context.
4.2.2 Cell cycle changes
With regard to the original hypothesis that DAB-Am16 might be cytotoxic
due to interaction with DNA, it was found in this study that DAB-Am16
causes cell cycle delay with accumulation of cells with S phase DNA content
on the DNA content histogram. Fig. 27 on page 88 allows an insight into
how S phase cells progress over time. The cell cycle distribution of tagged
original S phase cells and their progeny can be inferred from this figure.
If the cells are not disturbed by cytotoxic or cytostatic compounds, they
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leave the S phase and are mostly found either within G2/M oder G1 phase
around 24 h later. Given that the average doubling time of MiaPaCa-2 cells
is 18 h (Fig. 18), one can conclude that after 24 h, the previous S phase cells
have divided into daughter cells. These daughter cells then have passed the
S phase a second time to continue with the cell division cycle. The vast
majority of the overall cell population (88%) is BrdU-positive (first plot
in Fig. 27 while at any given time point within 30min only about 45%
of cells are capable of incorporating BrdU into DNA (first plot in Fig. 28
on page 89). As BrdU is stably incorporated into DNA, dividing cells will
“inherit” BrdU to daughter cells and thus the progeny of BrdU-tagged cells
also carries BrdU.
When a doubling time of a cell line is specified, the particular value does
not mean that each cell (and its progeny) requires that particular period
of time to pass the cell cycle, but rather the doubling time is an average
value for the whole cell sample. Within each cell population that is not
completely homogeneous, there will be cells that divide slower and cells
that divide faster than the average doubling time. Cancer cell lines are
prone to mutations due to the natural genetic instability of tumours, so
a cancer cell line will be genetically heterogeneous due to accumulation
of mutations over time. One can assume that most of those cells that
are found synthesizing DNA within an arbitrarily selected time period of
30min belong to the fast dividing subpopulation. Thus, within 24 h they
will have grown faster than most of the non-labelled cells (from a slower
growing subpopulation) and will produce more progeny (some of those that
were at the end of the S phase at the labelling time point might have even
divided twice). Furthermore, a certain part of the non-labelled cells might
have been senescent and thus would not be found among the viable cells
24 h later, but rather be gated out as disintegrated cells and debris during
data analysis. These two facts explain the great increase of the proportion
of labelled cells 24 h after labelling with BrdU occurred. When the cells
are treated with the inhibitor of DNA replication hydroxyurea, almost all
of them incorporate BrdU but the cells do not proceed to further DNA
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synthesis. This is consistent with the mechanism of action of hydroxyurea
that acts upon dNTP pool depletion. So hydroxyurea-treated cells are
capable of and ready for DNA synthesis but do not have the building blocks
for building up new DNA strands. Once the dNTP-analogue BrdU is added
to the surrounding medium, the cells that got stuck at the beginning of
the S phase rapidly use up this BrdU for DNA synthesis. When cells are
treated with DAB-Am16, a very interesting pattern is observed (Fig. 27).
At a low dendrimer concentration, there are three populations with a G1
DNA content: G1BrdUhigh, G1BrdUmed and G1BrdUlow. Furthermore, there
is one population with an S phase DNA content and two populations with a
G2 DNA content (G2BrdUhigh and G2BrdUmed). The G1BrdUmed population
does not appear within the control sample. These are cells that seem to
have taken up BrdU during the labelling process and then to have lost
some BrdU along with DNA or having proceeded to G1 and lost BrdU on
their way to this point. One possible explanation is that upon exposure to
DAB-Am16, some S phase cells became arrested in this phase and started to
undergo apoptosis after some time. In late apoptosis, the DNA content of
these cells would have started to drop (Darzynkiewicz et al. 1992), which not
only would have led to a lower DAPI fluorescence, but also to a decrease of
the amount of intracellular BrdU. According to this explanation, the “new”
population G1BrdUmed (as compared to the untreated control) is derived
from labelled cells that did not proceed with cycling but rather started
undergoing apoptosis. This idea is supported by the fact that at high
DAB-Am16 concentration (last plot in Fig. 27), the whole cell population
has shifted to the left compared to the untreated control, indicating a
collective loss of DNA by all cells. Looking at the G2 cells, two different
levels of BrdU fluorescence are observable, although there is no visible shift
in DAPI fluorescence at the lowest concentration. This might well be due
to the fact that the BrdU signal is amplified by the use of antibodies for
detection and thus accurately reflects even subtle changes in cellular BrdU
content, while DAPI fluorescence linearly corresponds to DNA content and
thus might not clearly reveal small changes of DNA content. The drop
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in BrdU fluorescence for G1BrdUmed cells is much more pronounced than
hat for G2BrdUmed cells, so it might well be that here a mix of apoptotic
G1 cells with subtle DNA content change as well as apoptotic S phase
cells with a more pronounced decrease of DNA content is seen. Further
experiments could help to track the populations by using different DNA
synthesis labels at different time points (e.g. BrdU and EdU) and by using
additional markers of cell cycle phases, e.g. cell cycle phase specific cyclins.
Interestingly, for both 5 and 15µg/ml DAB-Am16 concentrations, the
vast majority of cells appears to be labelled with BrdU if compared to
the positive and negative populations within the untreated control. The
previously mentioned suggestion that S phase cells would be preferentially
eliminated would predict the opposite outcome: the vast majority of cells
would be BrdU-negative. So the approach of cell cycle specific labelling of
cells before drug treatment allows a new insight and shows how easily results
of simple cell cycle profiling can be misinterpreted if not being combined
with additional methods for in-depth investigation. Certainly, intracellular
staining of DNA with dyes like propidium iodide or DAPI is a powerful and
easy flow cytometric method that enjoys great popularity among researchers,
but care should be taken not to overestimate the conclusions that can be
drawn solely from this staining.
From Fig. 27 it also becomes obvious that at 50 µg/ml DAB-Am16, not
only all the cells are shifted towards a decreased DNA content, but also only
two BrdU fluorescence intensities can be detected. The intermediate BrdU
population has disappeared. Furthermore, a greater percentage of the cells
appears BrdU negative as compared to the control. There are two different
scenarios that could lead to this result. The first possibility is that the higher
the DAB-Am16 concentration, the faster the cytotoxic processes occur. In
this case, leaving cells with lower concentration of DAB-Am16 for a longer
time would yield the same result as incubating cells for a short time with a
higher DAB-Am16 concentration. The second possibility is that DAB-Am16
exerts different effects depending on its concentration. For example, at
a lower dendrimer concentration, S phase cells may benefit and survive
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preferentially, applying additional protective mechanisms that allow them
to stop cycling for a longer time before committing apoptosis, in particular
due to activation of S phase checkpoints. The change to a quiescent state
would also explain why there are more RNAlow cells with S phase DNA
content than with any other DNA content in DAB-Am16-treated samples
(while the pattern for non-treated samples is completely opposite) which is
illustrated in Fig. 45 on page 108. At a higher concentration, the damage to
the cell might be overwhelming so that these protective mechanisms might
be insufficient to keep cells alive in such a preferential manner. Assuming
that one of the mechanisms of DAB-Am16 action is DNA binding, a low
concentration might not lead to a fast collapse of S phase cells while a high
concentration might not be efficiently counteracted by the cellular DNA
maintenance machinery, so the survival advantage of S phase cells would
disappear. Simultaneously, a higher DAB-Am16 concentration would also
increase cellular damage by other mechanisms, e.g. nanohole formation
within cell membrane (facilitating leakage of intracellular DNA and other
cellular content into the surrounding medium), introduction of holes into
intracellular organelles (e.g. mitochondria) and so on, leading to a collective
decrease of DNA content within all cells.
Fig. 28 introduces another aspect into the considerations about BrdU
fluorescence. First of all, there is a tendency to a decrease of the number of
DNA synthesizing cells with increasing DAB-Am16 concentration. Secondly,
the last plot shows in a particularly clear manner that within the non-DNA
synthesizing (BrdU negative) cells, two distinct populations appear. One
of them has a slightly lower fluorescence within the BrdU channel along
with a slightly lower DAPI fluorescence. As these cells belong to BrdU-
negative cells, the reason cannot be a release of BrdU. Rather, it should be
kept in mind that fluorescence measurements always record some cellular
autofluorescence along with marker-specific fluorescence. It is a known
fact that autofluorescence decreases during late apoptosis and can even be
used by its own to study kinetics of apoptosis (Wolbers et al. 2004). Along
with the slight decrease of DAPI fluorescence, this is another sign of the
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appearance of a large apoptotic population after treatment with high doses
of DAB-Am16. This factor could additionally have contributed to the drop
of fluorecence in the BrdU channel observed in Fig. 27.
Having seen that the percentage of DNA synthesizing cells decreases with
increasing DAB-Am16 concentration, another approach was to combine
these two markers with a mitosis marker. Histone H3 becomes phos-
phorylated at serine 10 at the end of G2/beginning of M phase. Figs. 30
and 31 not only confirm once again the severe decrease of DNA synthesis
upon DAB-Am16 treatment, but also reveal the depletion of mitosis after
a prolonged incubation of cells with a high concentration of DAB-Am16.
Thus, cells not only become increasingly unable to replicate their DNA, but
also loose the capability to divide into daughter cells if the DNA has already
been replicated. This indicates that not only G1/S phase checkpoints are
involved into proliferational arrest, but there is another checkpoint at G2
that abrogates cell division. The G2 checkpoint might become activated
upon incomplete or erroneous DNA replication or due to DNA damage.
Surprisingly, staining of the marker for DNA damage and stalled replica-
tion forks γ-H2A.X yields a negative result (Fig. 25 on page 85). H2A.X
becomes phosphorylated far upstream within the DNA damage response
pathway (Fig. 8 on page 41) and triggers the repair mechanisms. From the
other observations presented within this thesis as well as from the dendrimer
structure and its established applications, the assumption that it at least
partly acts via DNA interaction appears to be reasonable. However, it is
not known much about the nature of this assumed interaction, so it will be
subject of future investigation whether DAB-Am16 indeed interacts with
nuclear DNA in a way that prevents phosphorylation of histone H2A.X
because this interaction/damage might not be sensed by upstream pathway
members. Independently from the reasons for this lack of phosphorylation,
the absence of γ-H2A.X indicates that most probably DNA repair mech-
anisms are not initiated upon DAB-Am16 exposure. On the other hand,
although Omidi et al. (2005) also could not directly detect DNA damage
upon exposure to PPI dendrimers, they saw an upregulation of proteasome
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α4 (a DNA double-strand repair facilitator) upon exposure to these dendri-
mers (section 1.2.7). A more detailed investigation of DNA integrity and of
activation of DNA repair pathways caused by PPI dendrimers is required.
Another experiment showed that cell cycle delay was accompanied by a
decrease of the cyclin D1 level (Fig. 29 on page 91). The higher the con-
centration of DAB-Am16, the larger the population of cells with decreased
amount of cyclin D1. It is well known that cyclin D1 is quickly degraded
upon genotoxic stress (Agami et al. 2000; Pontano et al. 2008). The kinase
ATM is activated upon DNA damage, it in turn activats the F-box protein
FBXO31 which promotes degradation of cyclin D1 (Santra et al. 2009). If
this pathway is also true for DAB-Am16-induced cyclin D1 loss, then it
again remains to be clarified why phosphorylation of histone H2A.X which
would be part of the DNA damage signaling pathway that involves ATM
could not be detected. Strikingly, Jirawatnotai et al. (2011) showed that
apart from playing a major role in G1/S transition, cyclin D1 also facilitates
homologous recombination-mediated DNA repair by BRCA2-dependent
recruitment of RAD51 to DNA damage sites. This does not contradict the
notion of DNA damage-induced cyclin D1 degradation, as Jirawatnotai et al.
observed that it is the remaining low amount of cyclin D1 that contributes
to the repair process. It would be interesting to see if a colocalisation of
RAD51 and cyclin D1 can be observed upon DAB-Am16 treatment in order
to better understand if DAB-Am16 exerts its cytotoxic effect via genotoxic
stress and if DNA repair mechanisms are triggered even bypassing H2A.X
phosphorylation.
The effect of DAB-Am16 was also tested in vivo with MiaPaCa-2 tumour
xenografts in immunodeficient mice. The cell cycle profile of the control
tumours differs considerably from the in vitro profile. Tumour-derived cells
exhibit a distinct S phase peak that has not been observed in vitro. In view
of this fact, one should be very cautious when trying to transfer conclusions
drawn from experiments within a cell culture environment onto living
organisms. However, in this case, DAB-Am16 not only affects cell cycle in
vitro, but also alters the cell cycle profile of the xenograft tumour cells. In
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both cases, S phase cells appear to be most sensitive to the dendrimer. Cells
from 3 out of 4 DAB-Am16-treated tumours completely lack S phase and
have only a very small G2/M peak. Together with the immunohistochemical
observation that the proliferation marker Ki-67 is expressed with the same
frequency in treated and untreated tumour samples, it appears that in the
in vivo settings MiaPaCa-2 cells are arrested in G1 (not in the quiescent G0
state), but remain ready for further proliferation once the cause of the cell
cycle arrest (the dendrimer) would be withdrawn. It remains to be tested
in further experiments if this assumption is true. Furthermore, it would be
interesting to know if the disappearance of S phase cells in treated tumours
results from selective death of cells that were hit within this phase, or if the
cells continued their cell cycle until G1 and became arrested in that phase.
4.2.3 Apoptotic cell death and cell membrane permeabilisation
Much of the implications of the experiments conducted on apoptotic as-
pects of DAB-Am16 effects have been discussed in section 3.6, so only the
key points are to be highlighted in the current section. As described in
section 1.3.3, cell death can be the result of different pathways. Within
this project, it has been shown that apoptosis is triggered by DAB-Am16
exposure and particular attention was paid to the course of apoptotic events
that occur upon DAB-Am16 treatment. Using multicolour flow cytometry,
it has become evident that cell membrane permeabilisation, increase of
light side scatter and activation of caspase-3 are associated with cellular
demise caused by DAB-Am16. This is followed by the loss of mitochondrial
membrane potential, decreased forward scatter and finally disintegration of
the cell. This is true for all three cell lines tested. The results presented in
this thesis suggest that caspase-3 is activated prior to the collapse of ∆Ψm.
This is in line with the findings of Bossy-Wetzel et al. (1998); Karpinich,
Tafani, Rothman et al. (2002); Karpinich, Tafani, Schneider et al. (2006).
Apoptosis is a process that involves a molecular cascade, and cell death
itself occurs downstream of this cascade. One of the latest (necrotic)
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events is permeabilisation of the plasma membrane. Thus, cell death
via apoptosis is not an immediate reaction on the presence of cytotoxic
substances. Compromised cell membrane appeared within 20–25min after
addition of DAB-Am16 to the cell culture medium (Fig. 23 on page 81).
This time period is too short for the process of reception of apoptotic
trigger, apoptotic cascade and final cell disintegration. Thus, this quick
cell membrane damage can only be caused either by oncosis/necrosis or by
direct membrane damage by the dendrimer. As a number of experiments
have shown that cell death occurs via apoptosis in DAB-Am16-treated
cells (section 3.6), one can assume that DAB-Am16 directly damages
the cell membrane. This is supported by the literature (section 1.2.4).
According to the literature, PAMAM and other dendrimers cause lipid
bilayer destruction, either by extension of pre-existing membrane defects
or by creating new ones. The results presented in this thesis are a first
hint that membrane damage is also caused by DAB-Am16. Previous
experiments of our group showed that fluorescently labelled DAB-Am16
can be detected within the nucleus 30min after its addition to the culture
medium. This time frame corresponds very well with the data obtained
by observation of DAPI entrance. Furthermore, the observation that the
percentage of U87MG cells with apoptotic characteristics is increased after
30min exposure to DAB-Am16 (section 3.6.3) also supports the DAPI
entrance data. Additionally, as justified on page 102, there is evidence
that while the holes created by DAB-Am16 permit entrance of DAPI into
the cell, they are not large enough to allow leakage of large cytosolic
ingredients into the surrounding medium. This only happens during late
stage apoptosis (designated as secondary necrosis). Thus, although evidence
for cell membrane hole formation by DAB-Am16 was found within this
study, this process was not identified as the cause of cell death.
Oncotic cell death usually refers to an unspecific and fast cell death. Due
to its unspecificity, a molecule that can induce oncosis most probably will
do so in a range of different cell types and settings. On the other hand,
apoptosis relies on intracellular molecules that might or might not consider
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a signal to be apoptotic. A chemical that causes apoptosis in one particular
cell type or within one particular tissue will not necessarily also induce
apoptosis in other cell types. In fact, this is why cancer treatment fails in
many cases: tumour cells often gain resistance to apoptotic signals due to
genomic mutations. On the other hand, a compound that drives tumour
cells into apoptosis might not be that toxic to non-transformed cells. Thus,
the fact that DAB-Am16 triggers apoptosis rather than oncosis gives hope
to specificity of its action. However, it also raises concerns that cancer cells
with particular mutations within the apoptotic pathway might overcome
DAB-Am16 toxicity. For this reason, thorough investigation of how exactly
DAB-Am16 activates the apoptotic machinery will help to predict which
patients might benefit from its administration.
4.3 In vivo evaluation
The significance of in vitro work in the field of drug discovery to a large
extent depends on whether eventually this drug will be safe enough to
be administered in the clinical context while improving the outcome of
the patients. In particular, the new drug should have advantages over
existing drugs for the disease it is intended to target. Thus, the effect of
DAB-Am16 was also tested in vivo with MiaPaCa-2 tumour xenografts in
immunodeficient mice. The measured outcomes were kinetics of tumour
growth, toxicity and in vivo effect on the cell cycle profile of tumour
cells. Treatment effect was compared with the current chemotherapeutic
gold standard in treatment of pancreatic cancer, namely administration
of gemcitabine. One should point out that although gemcitabine remains
standard treatment for unresectable pancreatic adenocarcinoma, it is not
a curative treatment, but rather serves to prolong survival. Even under
gemcitabine treatment, the overall survival with chemotherapy alone is 9.2
months (Loehrer et al. 2011). Certainly, tumour xenografts in mice do
not reproduce the course of disease of spontaneously occurring tumours
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in humans. However, such studies allow a first assessment if a compound
should be further evaluated as a potential, promising new drug.
For the in vivo assessment, mice with growing MiaPaCa-2 xenografts
were divided into three groups: untreated control, DAB-Am16-administered
and gemcitabine-administered. Fig. 49 on page 112 shows that at the onset
of the treatment, the tumours of control and DAB-Am16-treated groups
had the same mean size, while the mean tumour size of the mice in the
gemcitabine group was slightly less, although not significantly. For the next
four days after the first injection, the DAB-Am16-treated mice exhibited
further tumour growth, although it was not as steep as the growth within
the control group. However, on day 14 the tumour size decreased to the
level of the first treatment day and remained approximately the same with
minor fluctuations until day 25 when the animals were sacrificed. From day
19, the difference between the control group and the two treated groups
became significant, and a steep tumour growth within the control group
was observed. There was no significant difference in tumour size between
the DAB-Am16 and the gemcitabine groups, although the tumour size
within the gemcitabine group remained slightly lower over the whole time
course. However, this might be due to the slightly smaller mean tumour size
at treatment onset. Evidently, DAB-Am16 had a beneficial effect on the
clinical outcome in this experiment that was similar to that of gemcitabine.
This result is in line with the report of Dufes et al. (2005) that A431
epidermoid carcinoma, LS174T colorectal adenocarcinoma and C33a cervix
carcinoma xenograft growth is delayed by administration of DAB-Am16,
thus corroborating the notion that further exploration of DAB-Am16 as a
potential anti-tumour agent is highly desirable.
Safety of DAB-Am16 administration was assessed by measurement of
animal weight and observation of animal behaviour. After the first injection
of DAB-Am16, a profound weight loss was detected. However, the weight
rose to the previous value one day later and remained stable over the whole
experimental period. In fact, the mean animal weight was higher than that
of control and of gemcitabine animals during the last three measurements.
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The behaviour of the animals appeared to be normal within all three groups.
There was one animal death within the DAB-Am16 group. However, the
reason for the death was unclear as one day before being found dead, this
animal behaved normally and showed neither signs of above-average distress
or discomfort nor signs of additional physical ailments. The corpse did not
allow any conclusions on possible death reasons, and an examination of the
organs did not show any abnormalities. Thus, it remains unclear if this
death was related to dendrimer toxicity. Overall, the toxicity profile can be
appraised as favourable.
Prior to sacrificing the mice, several pictures were taken of each tumour.
Later on, the tumours on the pictures were semi-quantitatively assessed
for vascularisation of the tumour. Tumour vascularisation is an important
target of anti-cancer therapies and a number of anti-angiogenic compounds
are used in cancer treatment (Linkous et al. 2012). It has been reported by
Al-Jamal et al. (2010) that poly-L-lysine (PLL) dendrimers exert an anti-
angiogenic effect in mouse tumour models. With DAB-Am16, a tendency
to decreased vascularisation can be concluded from the tumour photos.
However, the effect is weak and is likely not to be the main mechanism of
action.
As for the molecular investigation, the cell cycle profile of the control
tumours differs considerably from the in vitro profile. Tumour-derived cells
exhibit a distinct S phase peak that has not been observed in vitro. In view
of this fact, one should be very cautious when trying to transfer conclusions
drawn from experiments within a cell culture environment onto living
organisms. However, in this case, DAB-Am16 not only affects cell cycle
in vitro, but also alters the cell cycle profile of the xenograft tumour cells.
Interestingly, cells from 3 out of 4 DAB-Am16-treated tumours completely
lack S phase and have only a very small G2/M peak. It is not clear whether
this is due to selective elimination of S phase cells or if an arrest of the
cells within the G1 phase prevails. Further investigations on this issue is
necessary, e.g. by BrdU injection a short time before killing the animals and
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evaluation of the number of BrdU positive (even though maybe otherwise
dead) cells within the tumours.
Additionally to cell cycle analysis, immunohistochemical staining of parts
of the tumour for the proliferation marker Ki-67 is performed. Similar
expression was found in treated and untreated tumour samples, indicating
that the readiness to further proliferate is not affected by DAB-Am16.
Taken together these and the cell cycle results, it appears that in the in
vivo settings MiaPaCa-2 cells are arrested in G1 (not in the quiescent G0
state), but remain ready for further proliferation once the cause of the cell
cycle arrest (the dendrimer) would be withdrawn. This is a tremendously
important issue that has to be addressed within further experiments. It is
a commonly known problem that even after apparent disappearance of the
tumour upon chemotherapeutic treatment, a relapse can occur at a later
time, indicating that a subset of tumour cells is often able to persist for a
longer period of time. Additionally, it is also known that in some cases a
tumour rebound occurs after chemotherapeutic treatment associated with
remarkably accelerated tumour regrowth (Bourhis et al. 1994; El Sharouni
et al. 2003; Shaked et al. 2008). Based on the results of the DAB-Am16
study, it is conceivable that after DAB-Am16 withdrawal the tumour cells
that are virtually synchronized within the G1 phase and ready to resume
proliferation, would do so within a short time frame leading to a rebound
effect. This does not need to be the case, but it is an important issue for
future investigations.
The specificity of DAB-Am16 effects in the in vivo studies so far has
been remarkable. However, the reasons for this specificity remain obscure.
While selective targeting of transformed tumour cells on the molecular
level is possible, another explanation could be selective accumulation of the
dendrimer within the tumour microenvironment. Tumour growth relies on
an immense supply of nutrients and oxygen which can only be achieved by
the creation of new blood vessels (angiogenesis). The newly built capillaries
are fenestrated, i.e., their endothelial cells contain pores, and these pores
are larger than the pores of most other capillaries of the body. Thus,
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macromolecules can gain access to tumour environment through these
pores, while not being able to get into healthy tissue. Once the molecules
are within the tumour environment, they are not removed as efficiently as
they would be from other organs, as tumour tissue usually lacks efficient
lymphatic drainage. Altogether, this is called “enhanced permeability and
retention effect” (EPR) and accounts for the selective accumulation of
macromolecules, liposomes and nano-scaled drugs within the tumour tissue
(Greish 2010; Maeda et al. 2009; Matsumura et al. 1986). However, the
EPR effect only leads to preferential drug accumulation in tumour tissue
for drugs that escape renal clearance and that cannot cross endothelial
tight junctions of normal vasculature, thus setting a molecular cut-off of
approximately 20–40 kDa (Greish et al. 2003; Haag et al. 2006) which is well
above the size of DAB-Am16 (1.7 kDa). However, preferred accumulation
in tumour tissue could be aided by the positive charge of DAB-Am16. This
is because tumour vasculature as well as the outer membrane of tumour
cells are negatively charged (Ran et al. 2002; Szachowicz-Petelska et al.
2010). Once within the tissue, again, increased retention as stated by the
EPR effect would lead to DAB-Am16 accumulation at the tumour site,
providing the specificity observed during the in vivo studies.
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The work presented in this thesis contributes to the knowledge about the
action of DAB-Am16. However, there are still a lot of questions to be
answered and a lot of research to be done until the details of this pathway
will be unveiled. Furthermore, it remains to be clarified if other dendrimers
and in a broader way polymers might have a similar or even stronger anti-
cancer effect in vivo, and if yes, if the mechanism of action is the same. The
following topics constitute a selection of topics worth to be investigated.
5.1 Molecular pathways
A detailed investigation of the molecular players involved into cell cycle
disturbance and cellular demise was beyond the scope of this research
project. However, without any doubt this will be the next step on the
way to unravelling the effect of DAB-Am16 onto cells. In section 1.3.2, I
introduced the pathway that leads to S phase arrest in response to DNA
damage or stalled replication. Although no γ-H2A.X could be detected
after DAB-Am16 exposure of cells, I would not reject the idea of interaction
between nuclear DNA and the dendrimer, especially in view of the massive
cell cycle disturbance that has been observed predominantly within the
S phase. Thus, probing if other members of the pathway in Fig. 8 on
page 41 become activated after incubation of cells with DAB-Am16 would
be desirable. Furthermore, a more detailed investigation on the possible
occurrence of DNA damage with additional tests, e.g. the COMET assay
is a highly sensitive and versatile assay for probing a range of different
DNA damage modalities on the level of individual cells including those that
possibly would not be accompanied by histone H2A.X phosphorylation like
DNA crosslinking (N. P. Singh et al. 1988). Central players of DNA damage
response machinery like ATM, ATR, CHK1 and CHK2 should be examined,
along with a more in-depth investigation of the cell cycle after DAB-Am16
exposure. Cell cycle investigations could include double-labelling with
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dNTPs analogues, e.g. labelling S phase cells before addition of DAB-Am16
with BrdU and labelling S phase cells after DAB-Am16 exposure with
EdU within one sample. BrdU and EdU can then be detected in different
fluorescence channels to track the fate of S phase cells in a precise way.
Staining for cell cycle phase specific markers like particular cyclins could
help to discern the subtleties that cannot be seen just by DNA staining.
Within the presented work, it was shown that caspase-3 dependent
apoptosis is initiated upon DAB-Am16 exposure. However, caspase-3 is
situated quite far downstream of the apoptotic pathway. It is not known
how apoptosis is initiated upon DAB-Am16 treatment. Different initiator
caspases are activated by different apoptotic stimuli, so further dissecting
this pathway would help to understand the precise mode of action of
DAB-Am16.
Detailed kinetic studies would allow an insight into the speed with which
the cells get damaged. In particular, continuous imaging techniques of live
cells would allow to create a precise profile of how cells react to DAB-Am16.
New technologies like chipcytometry that can record changes of live cells
over time including changes in marker fluorescences could aid achieving
this aim.
5.2 Resistance mechanisms
As discussed in section 4.2.1, a small population of cells within each tested
cell line appears to be resistant to DAB-Am16-induced cell death. It is
of tremendous importance to understand which mechanisms contribute to
the resistance. This knowledge would help to choose those patients that
will most probably benefit from DAB-Am16 in clinical trials, and it might
become possible to combine DAB-Am16 with other drugs that would act
against additional molecular targets and eliminate the DAB-Am16-resistant
cells. Furthermore, the selection of the treatment regimen also depends on
this knowledge. For example, metronomic therapy, reviewed in Pasquier
et al. (2010), defines a comparatively novel cancer therapy schedule based
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on the the observation that anti-angiogenic as well as some other drugs
with specific mechanisms of action exert a better anti-cancer effect when
being administered almost continuously for a long period of time at low
doses instead of following the classical schedule of high dose intermittent
chemotherapy blocks. Testing different treatment schedules for DAB-Am16
in vitro (continuous vs. intermittent exposure, combination of different
treatment and recovery times with different drug concentrations) to find the
schedule that eliminates even the currently resistant subpopulation would
contribute to the development of a suitable administration schedule in
clinical trials. Time-resolved studies of apoptosis and cell cycle disturbance
would further help to decide on the best treatment modalities.
5.3 Entry into the cell
At present, there is no clear answer to the question how DAB-Am16 gains
access to the interior of the cell. Sections 1.2.4 and 1.2.5 describe that
evidence for both nanohole formation in the cell membrane as well as
for endocytotic uptake exists. Most probably, the mechanism depends
on the polymer/dendrimer tested, on the cell line used for the tests, the
polymer/dendrimer concentration and other factors. Most of the studies
that have been conducted in this field have looked at PAMAM dendrimers,
and only very few studies involved PPI dendrimers. Thus, there is a need
for thorough investigation on the cell entrance mechanism of DAB-Am16.
Preliminary experiments with scanning ion-conductance microscopy showed
that this technique is capable of visualizing cell membrane defects in the
nanometer range. As this scanning technique does not involve any contact
between the cell surface and the microscope parts, and it furthermore
allows recording of the cells within their natural environment for long
time periods, it could reveal the existence or lack of holes within the cell
membrane, and in case of their existence this technique would allow insight
into kinetics of hole occurrence as well as help to determine if these holes
are transient or permanent (and thus, if they actually cause the cell death
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or not). A range of available endocytosis markers and inhibitors in turn
makes it possible to investigate cell entrance from this point of view. Finally,
fluorescent labelling of dendrimers, e.g. with dye NHS esters, along with
fluorescent labelling of intracellular compartments could help to visualize
the intracellular localisation of the dendrimer at particular time points or
even over a continuous period of time.
5.4 Comparison with non-tumour cells
The work presented in this thesis was aimed to shed light onto the mechan-
ism of action of DAB-Am16. However, in terms of cancer drug development,
it is important that the drug not only triggers death of tumour cells but
also spares healthy tissue. A common problem in cancer treatment is that
chemotherapeutics cause organ toxicity, and in particular bone marrow
toxicity. This hematopoietic toxicity is the cause of immune suppression
after treatment with cancer chemotherapeutics and makes the patient par-
ticularly susceptible to severe infections that can be fatal. Decreased blood
cell count requires frequent blood transfusions that can lead to iron over-
load and put the patients at risk of getting infected with hepatitis viruses,
HIV and similar diseases transferred with infected blood. Furthermore,
immune depletion makes it impossible to administer cancer therapeutics
continuously. They are rather administered over a short time, followed by
a break that allows the patients’ organism to recover. However, cancer cells
get the opportunity to further divide during this time as well. If the tumour
cells recover faster than the healthy tissues, the disease becomes incurable.
Research on protection of healthy tissues is under way. Recently, Adair
et al. (2012) developed a gene therapy method to make the patient’s hem-
atopoietic stem cells less susceptible to chemotherapeutics. In this study,
genetic modifications of patients’ own hematopoietic stem and progenitor
cells and the following autologous bone marrow transplantation with the
genetically modified cells allowed the physicians to administer high doses
of the alkylating agent temozolamide together with the inhibitor of methyl-
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guanine methyltransferase (MGMT) O6-benzylguanine (O6BG). MGMT
was overexpressed in the glioblastoma cells of these patients, making the
tumour resistant against temozolamide by increased repair of DNA damage
caused by this drug. However, administration of O6BG to deplete this
resistance would have resulted in severe bone marrow toxicity. Successful
engraftment of O6BG-resistant hematopoietic cells considerably alleviated
bone marrow toxicity of O6BG. Median survival time of glioblastoma pa-
tients since diagnosis is 12 months, with unmethylated MGMT promoter
being prognostically unfavourable (Krex et al. 2007). Two participants of
this study survived 14 and 20 months, respectively, while the 3rd is still
alive without disease progression after 34 months. If these results can be
repeated in large-scale studies, this could be considered as a break-through
in glioblastoma therapy.
This example illustrates the importance of drug selectivity for treatment
success. Thus, it does not suffice to develop a drug that effectively eliminates
cancer cells but it is crucial to ensure that this drug lacks organ toxicity. The
mice in the in vivo experiments with DAB-Am16 did not exhibit apparent
toxicity. One death was observed, but the relation to treatment remains
doubtful. Importantly, this observation gives hope that DAB-Am16 might
exert selective toxicity against tumour cells. If this will be the case in clinical
trials, development of concomitant organ-protective therapy would become
obsolete. Further investigations of this issue in in vitro settings are necessary.
In fact, preliminary experiments have been conducted with WI-38 human
embryonic lung fibroblasts in our group which revealed a higher EC50
value and thus lower sensitivity of these non-cancer cells to DAB-Am16.
However, although this cell line is not derived from a tumour, it has the
capability of long-term division (approx. 50 population doublings) in tissue
culture. In general, unlimited cell division is a feature of cancer cells, while
untransformed cells have a very limited divisional capability. Thus, one can
assume that WI-38 cells are not a typical representative of healthy cells. To
examine the effect of DAB-Am16 on healthy tissue, primary untransformed
cells from different tissues should be used. Comparative cytotoxicity assays
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should be performed on cancer cells and on healthy primary cells from
different tissues as well as blood cells (hemolysis assays). However, one
should keep in mind that toxicity against healthy tissue might be decreased
in vivo compared to in vitro due to selective accumulation of DAB-Am16
within the tumour environment and thus spatial sparing of healthy organs.
Approaches to examine this issue are described in section 5.6.
5.5 Effectivity and safety of structurally related
macromolecules
DAB-Am16 is a PPI dendrimer, and as we have seen that DAB-Am16
exerts an anti-cancer effect in xenografts, one may reasonably expect that
other dendrimers might have a similar effect. In general, the toxicity of
dendrimers increases with generation number, as described in section 1.2.3.
However, Moroson (1971) showed that increasing cationic charge also means
increasing effectivity against tumours. By comparison of different types of
structurally related macromolecules (PAMAM dendrimers, PLL dendrimers,
linear and branched polymers) it might be possible to find a compound
that outmatches DAB-Am16 when it comes to the balance of effectivity
and safety. Thus, systematic in vitro comparison with subsequent in vivo
tests of promising drug candidates should be performed.
5.6 Further in vivo studies
The in vivo investigation of DAB-Am16 has just begun. Cancer is a general
term for a very heterogeneous set of diseases. Tumours can be derived
from almost each cell type, and combinations of many different mutations
can lead to the same result: uncontrolled cell division and tumour growth.
Selection of suitable treatment modalities depends on the tumour origin,
on the mutations that led to tumour formation, on the stage of disease and
on the individual situation of the patient. No single drug is conceivable
that would be effective against all tumour types. To account at least for a
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part of the disease varieties, DAB-Am16 should be tested against a large
selection of xenografts. This would help to decide upon tumour types that
respond best to this compound and that one should focus on when aiming
for application in humans. Another aspect that the xenograft used for the
present study was injected subcutaneously. Orthotopic xenografts that
are grown within same tissue environment that the tumour cells originate
from would mimic the clinical settings better than subcutaneous tumours.
Inclusion of metastatic disease models will show if DAB-Am16 can prevent
metastasis or if it can act effectively against existing metastatic lesions. It
is important to follow up animals where DAB-Am16 led to disappearance
of the tumour, as a relapse might occur later. Also, a comparison of growth
kinetics of non-treated tumours with tumours that previously had been
treated with DAB-Am16 for a limited time would help to understand if an
accelerated tumour cell growth might be an issue in case treatment with
DAB-Am16 would have to be discontinued.
Another approach would be to get away from xenograft usage and to apply
DAB-Am16 onto tumours derived from the same species as the test animals
or even onto naturally occurring tumours. Although animal organisms,
cells and thus also tumours differ from humans, the fact that the animals
would bear the natural immune system, the tumours would develop within
the natural microenvironment including normal tissue vascularisation, and
naturally occuring tumours would not be as homogeneous as tumours
derived from a single cell line might improve prognostic relevance of these
studies. To get even closer to human clinical settings, animals with more
similar disease course to humans than mice could be used. In fact, plans
exist to further test DAB-Am16 as an anti-cancer agent for canine patients
of veterinary clinics. The knowledge derived from such experience would
be invaluable for planning clinical studies with human patients.
In section 4.3, the question was raised whether DAB-Am16 impedes
tumour growth while sparing healthy tissues due to a modification of
the EPR effect. This issue should be addressed in future studies. To
investigate if this plays a role in selective tumour targeting by DAB-Am16,
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biodistribution of the dendrimer should be investigated. To get to the
bottom of the reasons for it, the distribution of the dendrimer among
the organs over time needs to be investigated. For thorough investigation
of DAB-Am16 specificity, determination of in vivo biodistribution of the
dendrimer is required. Whole animal bioimaging after administration of
fluorescently labelled DAB-Am16 would reveal the distribution between
the organs in a time-resolved manner.
Systematic and extensive testing of the responding and not-responding tu-
mours for differences in cell cycle progression, cell proliferation, expression of
proliferation as well as apoptotic markers and examination of tumour vascu-
larization will help to understand if the mechanism of action of DAB-Am16
in vivo is similar to that in vitro. Just as S phase cells can be identified in
cell culture by BrdU incorporation, mice can also be injected with BrdU
before being sacrificed, so that the proportion of S phase tumour cells
can be determined and compared between different tumours and between
responders/non-responders.
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Within the project described in this thesis, the dendrimer DAB-Am16 was
characterised from the chemical and the biological point of view. 1H, 16C
and COSY NMR, MS/MS, MALDI-TOF, and elemental analysis showed
that DAB-Am16 retains its chemical structure after prolonged periods of
use as well as within a wide range of storage temperatures.
According to in vitro cytotoxicity assays, DAB-Am16 exerts a pro-
found cytotoxic effect on MiaPaCa-2, U87MG, A431, A2780, H1299 and
MDAMB231 cancer cell lines. Furthermore, it has a lasting inhibitory effect
on cell division as indicated by diminished growth of new cell colonies. The
EC50 steeply decreases within the first doubling time of the cell line, while
remaining stable during longer exposure of cells to DAB-Am16. Several
explanations are conceivable in the face of these results. It remains to be
investigated whether the concepts of cancer stem cells or of acquisition of
reversible epigenetic modifications are applicable in this case.
Detailed examination of the cell cycle changes after DAB-Am16 exposure
revealed severe disturbance of the cell cycle. At low DAB-Am16 concentra-
tions, cell cycle is delayed, while high dendrimer concentrations completely
abrogate DNA synthesis and mitosis. Some evidence has been presented for
S phase cells being more resistant to death at low DAB-Am16 concentrations
by acquiring a quiescent-like state, while these cells are more susceptible to
DAB-Am16-induced cell death at high dendrimer concentrations. However,
this issue is to be investigated in greater detail.
A number of apoptotic characteristics were observed that together yield
strong evidence for apoptotic processes being elicited upon DAB-Am16
exposure of cancer cells. This implies a specific mode of triggering cell
death, giving rise to the hope that cancer cells might be more efficiently
targeted by DAB-Am16 than non-transformed cells. DNA damage was
found not to be involved in the process of cellular demise. Hole formation in
the plasma membrane is likely to be the way the dendrimer enters the cells,
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but this also does not seem to be the reason for cell death. The precise
pathway needs to be examined in further detail.
Finally, in vivo testing was undertaken to assess the effect of DAB-Am16
on human pancreatic cancer xenografts in mice. The dendrimer was at
least as effective as the gold standard gemcitabine, while showing a good
safety profile. The tumour size of dendrimer-treated mice remained stable
over time, while the non-treated tumours exhibited fast growth. Due to
the relatively small cohort of mice this experiment should be repeated on a
larger scale. Modifications of the experimental setup for gaining additional
information have been suggested in this thesis. However, this thesis presents
strong evidence for a specific anti-tumour effect of DAB-Am16 in vivo.
On the whole, the data presented in this thesis implicates the need
to continue investigations on dendrimers as a novel class of therapeutic
compounds, and specifically on DAB-Am16 as a promising drug candidate
in cancer therapy.
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